Lysine acetyltransferase 6A (KAT6A) inhibitors, their combinations, and their use

Abstract

This specification describes a method for treating cancer using a low-molecular-weight lysine acetyltransferase 6a (KAT6A) inhibitor and additional agents.

Description

[Technical Field]

[0001] cross reference This patent application claims the interests of International Application PCT / CN2023 / 089277, filed on 19 April 2023, and International Application PCT / CN2024 / 086020, filed on 3 April 2024, both of which are incorporated herein by reference in their entirety. [Background technology]

[0002] Lysine acetyltransferase 6A (KAT6A) belongs to the MYST family of acetyltransferases and was first discovered about 25 years ago. KAT6A regulates fundamental cellular processes, including gene transcription, cellular senescence, cardiac septal development, memory T cell diversity, and maintenance of normal hematopoietic stem cells. Dysregulation of KAT6A acetyltransferase activity or aberrant expression of KAT6A is associated with oncogenic function in many cancers, including leukemia, glioma, endometrial serous carcinoma, and breast cancer. Therefore, compounds that inhibit KAT6A are potential agents for treating various cancers.

[0003] First-line treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4 / 6i) and endocrine therapy (ET) has improved long-term outcomes in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Following CDK4 / 6i and ET, oncologists typically treat patients with the longest possible continuous ET-based regimen, as it is usually less toxic than chemotherapy. Unfortunately, acquired tumor resistance to ET is common.

[0004] Molecular dysregulation of KAT6A has been observed in several cancers, including amplification in breast, lung, and ovarian cancers and oncogenic fusions in AML. In breast cancer, KAT6A has been found to be amplified and / or overexpressed in 10-15% of the ER-positive breast cancer population. KAT6A is a direct transcriptional regulator of ESR1, and amplification is associated with a worse clinical outcome. The first- and second-line treatment options for HR-positive / HER2-negative breast cancer include endocrine therapy, CDK4 / 6 inhibitors, and targeted therapy. Patients with refractory diseases have few treatment options. Therefore, KAT6A is considered a clinically meaningful therapeutic target for ER-positive / HER2-negative breast cancer. Summary of the Invention

[0005] In one aspect, a method of treating cancer in a subject in need thereof is provided herein, the method comprising administering to the subject (a) a compound of formula (I)

[0006]

Chemical Formula

[0007] In another embodiment, a method for treating cancer in a subject requiring treatment is provided herein, the method being used in the subject, (a) 2,4-dimethoxy-N-(4-methoxy-6-(thiazole-2-yloxy)benzo[d]isoxazole-3-yl)-6-methylpyridine-3-sulfonamide

[0008] [ka] or a pharmaceutically acceptable salt thereof, (b) Additional medications The process includes administering [the substance].

[0009] In another embodiment, a method for treating cancer in a subject requiring treatment is provided herein, the method being used in the subject, (a) 2,4-dimethoxy-N-(4-methoxy-6-(thiazole-2-yloxy)benzo[d]isoxazole-3-yl)-6-methylpyridine-3-sulfonamide

[0010] [ka] or a pharmaceutically acceptable salt thereof, (b) Erasestrant The process includes administering [the substance].

[0011] In a further embodiment, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer is provided herein, the medicament being formulated to be administered in combination with an additional agent.

[0012] In further embodiments, the use of compounds of formula (I) or pharmaceutically acceptable salts thereof and additional agents in the manufacture of pharmaceuticals for treating cancer is provided herein.

[0013] In a further embodiment, the use of compound 57 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer is provided herein, the medicament being formulated to be administered in combination with an additional agent.

[0014] In further embodiments, the use of compound 57 or pharmaceutically acceptable salts thereof and additional agents in the manufacture of pharmaceuticals for treating cancer is provided herein. [Brief explanation of the drawing]

[0015] Novel features of the present invention are described in detail in the appended claims. A better understanding of the features of the present invention will be obtained by referring to the following detailed description, which describes exemplary embodiments in which the principles of the present invention are utilized, and to the appended drawings. [Figure 1] The changes in tumor volume in PDX models treated with the vehicle and the compounds disclosed herein are shown. [Figure 2] The relative changes in body weight in the vehicle and PDX models treated with the compounds disclosed herein are shown. [Figure 3A] This shows the normalized percentage of viable breast cancer ER+ / KAT6ahigh ZR-75-1 cells compared to control treatment, when treated with compound 57 (IC10 / IC25 / IC50 / IC75), elastosterant, or compound 57 + elastosterant. [Figure 3B] The dose-response curves for 57 compounds, either alone or in combination with elastrant, are shown (IC25, 56 nM). [Figure 4] This shows a statistical analysis of cytotoxicity data obtained from the breast cancer ER+ / KAT6ahigh ZR-75-1 cell line. [Figure 5] This shows the Combination Index plot of Combination Index, which illustrates the relationship between CI and the fraction affected by the drug combination (Fa) (fraction of dead cells). [Figure 6] The Compusyn table of synergies between compound 57 and elastrant in the ER+ / KAT6ahigh breast cancer ZR-75-1 cell line using Combenefit software demonstrates the evaluation of synergies via the Loewe algorithm. [Modes for carrying out the invention]

[0016] definition The following description includes specific details to fully understand the various embodiments. However, those skilled in the art will understand that the disclosure can be carried out without these details. In other examples, well-known structures are not shown or described in detail to avoid unnecessarily complicating the description of embodiments. Unless the context specifically requires otherwise, the word “comprise” and its variations (e.g., “comprises” or “comprising”) throughout the following specification and claims shall be interpreted in an open, comprehensive sense, i.e., “including, but not limited to, ~”. Furthermore, the headings provided herein are for convenience only and shall not construed as to the scope or meaning of the invention of the subject matter.

[0017] Any reference herein to “several embodiments” or “one embodiment” means that any particular characteristic, structure, or feature described in relation to an embodiment is included in at least one embodiment. Thus, the phrases “(in one embodiment)” or “(in one embodiment)” appearing throughout this specification do not necessarily all refer to the same embodiment. Furthermore, any particular characteristic, structure, or feature may be combined in any suitable manner in one or more embodiments. Similarly, as used herein and in the appended claims, the singular “a,” “an,” and “the” refer to multiple objects unless their content explicitly indicates otherwise. Also note that the term “or” is usually used to mean “and / or” unless their content explicitly indicates otherwise.

[0018] The following terms, as used herein, have the meanings set forth below, unless otherwise specified.

[0019] "Oxo" refers to O.

[0020] "Carboxyl" refers to the -COOH group.

[0021] "Cyano" refers to -CN.

[0022] "Alkyl" refers to a linear or branched saturated hydrocarbon monoradical having 1 to about 10 carbon atoms, more preferably 1 to 6 carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl, and hexyl, as well as long alkyl groups such as heptyl and octyl. Wherever it appears herein, it is always referred to as "C1-C6 alkyl" or "C 1-6 Numerical ranges such as "alkyl" mean that an alkyl group can consist of one carbon atom, two carbon atoms, three carbon atoms, four carbon atoms, five carbon atoms, or six carbon atoms, but this definition also includes the use of the term "alkyl" when a numerical range is not explicitly stated. In some embodiments, alkyl is C 1-10 It is alkyl. In some embodiments, alkyl is C 1-6 It is alkyl. In some embodiments, alkyl is C 1-5 It is alkyl. In some embodiments, alkyl is C 1-4 It is alkyl. In some embodiments, alkyl is C 1-3It is alkyl. Unless otherwise specified herein, alkyl groups may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkyl groups are optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkyl groups are optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, alkyl groups are optionally substituted with halogen.

[0023] "Alkenyl" refers to a linear or branched hydrocarbon monoradical having one or more carbon-carbon double bonds and 2 to about 10 carbon atoms, more preferably 2 to about 6 carbon atoms. The group may have either a cis or trans structure with respect to the double bond and should be understood to include both isomers. Examples include, but are not limited to, ethenyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, and 1,3-butadienyl. Whenever it appears herein, it is always referred to as "C2-C6 alkenyl" or "C 2-6Numerical ranges such as "alkenyl" mean that the alkenyl group may consist of 2, 3, 4, 5, or 6 carbon atoms, but this definition also includes the use of the term "alkenyl" when a numerical range is not explicitly stated. Unless otherwise specified herein, the alkenyl group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkenyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.

[0024] "Alkynyl" refers to a linear or branched hydrocarbon monoradical having one or more carbon-carbon triple bonds and 2 to about 10 carbon atoms, more preferably 2 to about 6 carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, and 1,3-butadiinyl. Wherever it appears herein, it is always referred to as "C2-C6 alkynyl" or "C 2-6Numerical ranges such as "alkynyl" mean that the alkynyl group may consist of 2, 3, 4, 5, or 6 carbon atoms, but this definition also includes the use of the term "alkynyl" when no numerical range is specified. Unless otherwise specified herein, the alkynyl group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen.

[0025] "Alkylene" refers to a straight-chain or branched-chain divalent hydrocarbon chain. Unless otherwise specified herein, alkylene groups may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, alkylene is optionally substituted with halogen.

[0026] "alkoxy" is the formula -OR a It refers to the radical of R ais an alkyl radical as defined. Unless otherwise specified herein, the alkoxy group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkoxy is optionally substituted with a halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy is optionally substituted with a halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with a halogen.

[0027] "Aryl" refers to a radical derived from a hydrocarbon ring system containing 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, and may include a condensed ring system (where the aryl is bonded via aromatic ring atoms when condensed in a cycloalkyl or heterocycloalkyl ring) or a bridging ring system. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl(phenyl). Examples of aryl radicals, but not limited to, derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluorantene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless otherwise specified herein, aryls may be optionally substituted with, for example, halogens, aminos, nitriles, nitros, hydroxyls, alkyls, alkenyls, alkynyls, haloalkyls, alkoxys, carboxyls, carboxylates, aryls, cycloalkyls, heterocycloalkyls, heteroaryls, etc. In some embodiments, aryls are optionally substituted with halogens, methyls, ethyls, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, aryls are optionally substituted with halogens, methyls, ethyls, -CN, -CF3, -OH, or -OMe. In some embodiments, aryls are optionally substituted with halogens.

[0028] "Cycloalkyl" refers to a partially or completely saturated monocyclic or polycyclic carbon ring, which may include condensed (when condensed with an aryl or heteroaryl ring, the cycloalkyl is bonded by non-aromatic ring atoms) ring systems, spirocyclic systems, or bridging ring systems. In some embodiments, the cycloalkyl is completely saturated. Typical cycloalkyls include, but are not limited to, those with 3 to 15 carbon atoms (C3-C3). 15Fully saturated cycloalkyl or C3-C 15 Cycloalkenyl), 3-10 carbon atoms (C3-C 10 Fully saturated cycloalkyl or C3-C 10Examples of cycloalkyls include cycloalkenyls, cycloalkyls having 3 to 8 carbon atoms (C3-C8 fully saturated cycloalkyl or C3-C8 cycloalkenyl), cycloalkyls having 3 to 6 carbon atoms (C3-C6 fully saturated cycloalkyl or C3-C6 cycloalkenyl), cycloalkyls having 3 to 5 carbon atoms (C3-C5 fully saturated cycloalkyl or C3-C5 cycloalkenyl), or cycloalkyls having 3 to 4 carbon atoms (C3-C4 fully saturated cycloalkyl or C3-C4 cycloalkenyl). In some embodiments, the cycloalkyl is a 3 to 10-membered fully saturated cycloalkyl or a 3 to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3 to 6-membered fully saturated cycloalkyl or a 3 to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5 to 6-membered fully saturated cycloalkyl or a 5 to 6-membered cycloalkenyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, dekalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, as well as 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise specified herein, cycloalkyls are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.In some embodiments, the cycloalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted with halogen.

[0029] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodine. In some embodiments, the halogen is fluoro or chloro. In some embodiments, the halogen is fluoro.

[0030] "Haloalkyl" refers to alkyl radicals as defined above, which are substituted by one or more halo radicals, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc.

[0031] "Hydroxyalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyls include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.

[0032] "Aminoalkyl" refers to an alkyl radical, as defined above, that is substituted with one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyls include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.

[0033] A "heteroalkyl" refers to an alkyl group in which one or more of the alkyl backbone atoms are atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof. The heteroalkyl is bonded to the rest of the molecule at the carbon atoms of the heteroalkyl. In one embodiment, the heteroalkyl is a C1-C6 heteroalkyl, which consists of 1 to 6 carbon atoms and one or more atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof, and the heteroalkyl is bonded to the rest of the molecule at the carbon atoms of the heteroalkyl. Examples of such heteroalkyls are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or -CH2CH2N(CH3)2. Unless otherwise specified herein, heteroalkyls are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroalkyls are optionally substituted with halogens.

[0034] A "heterocycloalkyl" refers to a 3-24 membered, partially or fully saturated ring radical containing 2-23 carbon atoms and 1-8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, silicon, and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl contains 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl contains 1-3 heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl contains 1-3 nitrogen atoms. In some embodiments, the heterocycloalkyl contains 1 or 2 nitrogen atoms. In some embodiments, the heterocycloalkyl contains 1 nitrogen atom. In some embodiments, the heterocycloalkyl contains 1 nitrogen atom and 1 oxygen atom. Unless otherwise specified herein, heterocycloalkyl radicals may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include condensed ring systems (when condensed with an aryl or heteroaryl ring, the heterocycloalkyl is bonded via a non-aromatic ring atom), spirocyclic ring systems, or bridging ring systems, and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized, and the nitrogen atom may be optionally quaternized. Typical heterocycloalkyls include, but are not limited to, those with 2 to 15 carbon atoms (C2-C2). 15 Fully saturated heterocycloalkyl or C2-C 15 Heterocycloalkenyl), 2-10 carbon atoms (C2-C 10 Fully saturated heterocycloalkyl or C2-C 10Examples include heterocycloalkyls having heterocycloalkenyls, 2-8 carbon atoms (C2-C8 fully saturated heterocycloalkyl or C2-C8 heterocycloalkenyl), 2-7 carbon atoms (C2-C7 fully saturated heterocycloalkyl or C2-C7 heterocycloalkenyl), 2-6 carbon atoms (C2-C6 fully saturated heterocycloalkyl or C2-C7 heterocycloalkenyl), 2-5 carbon atoms (C2-C5 fully saturated heterocycloalkyl or C2-C5 heterocycloalkenyl), or 2-4 carbon atoms (C2-C4 fully saturated heterocycloalkyl or C2-C4 heterocycloalkenyl). Examples of such heterocycloalkyl radicals include, but are not limited to, azilidinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, and 4-piperazinyl. Examples include lidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianil, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term "heterocycloalkyl" also includes, but is not limited to, all cyclic forms of carbohydrates, including monosaccharides, disaccharides, and oligosaccharides. In some embodiments, heterocycloalkyls have 2 to 10 carbon atoms in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it should be noted that the number of carbon atoms in a heterocycloalkyl is not the same as the total number of atoms (i.e., the skeletal atoms of the heterocycloalkyl ring) that make up the heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8-membered fully saturated heterocycloalkyl.In some embodiments, the heterocycloalkyl is a 3- to 7-membered fully saturated heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered fully saturated heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered fully saturated heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered fully saturated heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless otherwise specified herein, heterocycloalkyls may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc., as described below. In some embodiments, heterocycloalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heterocycloalkyls are optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heterocycloalkyls are optionally substituted with halogen.

[0035] A "heteroaryl" refers to a 5-14 membered cyclic radical comprising 1-13 carbon atoms, 1-6 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl contains 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl contains 1-3 heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl contains 1-3 nitrogen atoms. In some embodiments, the heteroaryl contains 1 or 2 nitrogen atoms. In some embodiments, the heteroaryl contains 1 nitrogen atom. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic cyclic system, which may include a condensed (when condensed with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded via aromatic ring atoms) cyclic system or a bridging cyclic system, and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized, and the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl is a 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5-membered heteroaryl.Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranil, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanil, benzonaphthofuranil, benzoxazolyl, benzodioxolyl, benzodioxynil, benzopyranil, benzopyranonil, benzofuranil, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinil, dibenzofuranil, dibenzothiophenyl, furanil, furanonil, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, Includes isoindolyl, indolinyl, isoindolyl, isoquinolyl, indolidinyl, isoxazolyl, naphthilidinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxyranil, 1-oxidepyridinyl, 1-oxidepyrimidinyl, 1-oxidepyradinyl, 1-oxidepyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxadinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridadinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specified herein, heteroaryls may be optionally substituted with, for example, halogens, aminos, nitriles, nitros, hydroxyls, alkyls, alkenyls, alkynyls, haloalkyls, alkoxys, carboxyls, carboxylates, aryls, cycloalkyls, heterocycloalkyls, heteroaryls, etc. In some embodiments, heteroaryls are optionally substituted with halogens, methyls, ethyls, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroaryls are optionally substituted with halogens, methyls, ethyls, -CN, -CF3, -OH, or -OMe.In some embodiments, the heteroaryl group is optionally substituted with a halogen.

[0036] The terms “optional” or “optionally” mean that the events or circumstances described below may or may not occur, and that this description includes examples in which such events or circumstances occur and examples in which they do not. For example, “optionally substituted alkyl” means “alkyl” or “substituted alkyl” as defined above. Furthermore, an optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at a level in the range between full substitution and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.). Those skilled in the art will understand that with respect to any group containing one or more substituents, such group is not intended to introduce any substitution or substitution pattern that is sterically impractical and / or synthetically impossible. Therefore, any substituent described should generally be understood to have a maximum molecular weight of approximately 1,000 daltons, and more specifically, up to approximately 500 daltons.

[0037] An "effective dose" or "therapeutic effective dose" refers to the amount of a compound administered to a mammalian subject, either as a single dose or as part of a series of doses, that is effective in producing the desired therapeutic effect.

[0038] As used herein, the term “synergistic effect” means, when used in relation to a combination of drugs, any measured effect of a combination that is greater than the effect predicted from the sum of the effects of the individual drugs.

[0039] "Treatment" of an individual (e.g., a mammal such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. In some embodiments, treatment includes the administration of a pharmaceutical composition after the onset of a pathological event or contact with a pathogen, and includes stabilization of the disease (e.g., preventing the disease from worsening) or mitigation of the disease.

[0040] As used herein, the term “acceptable” for a formulation, composition, or component means that it does not have any lasting adverse effects on the health condition of the subject being treated.

[0041] As used herein, terms such as “administer,” “administering,” and “administration” refer to methods that may be used to enable the delivery of a compound or composition to a desired site of biological action. These methods include, but are not limited to, oral, intraduodenal, parenteral infusion (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular, or intravenous drip), topical, and rectal administration. Those skilled in the art will be familiar with the administration techniques that can be used with the compounds and methods described herein. In some embodiments, the compounds and compositions described herein are administered orally.

[0042] As used herein, the terms “enhance” or “to augment” mean to increase or prolong a desired effect in terms of either potency or duration. Therefore, with respect to enhancing the effect of a therapeutic agent, “to augment” refers to the ability to increase or prolong the effect of another therapeutic agent on a system in terms of either potency or duration. “Enhancing dose” as used herein refers to an amount sufficient to enhance the effect of another therapeutic agent on a desired system.

[0043] The terms “subject” or “patient” encompass mammals. Examples of mammals include, but are not limited to, classes of mammals: humans, non-human primates such as chimpanzees, as well as other apes and monkey species, domesticated animals such as cattle, horses, sheep, goats, and pigs, pet animals such as rabbits, dogs, and cats, and any member of laboratory animals such as rats, mice, and guinea pigs. In one aspect, a mammal is a human.

[0044] compound Compounds of formula (I), (I'), (Ia), (II), (III), (IV), (V), or (VI), or pharmaceutically acceptable salts or solvates thereof, are described herein as KAT6A inhibitors that are useful in treating diseases or disorders associated with KAT6A inhibition. In some embodiments, compounds of formula (I), (I'), (Ia), (II), (III), (IV), (V), or (VI), or pharmaceutically acceptable salts or solvates thereof, are useful in treating cancer.

[0045] In some embodiments, formula (I)

[0046] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, Y 1 CR 1a or N, Y 2 CR 2a or N, Y 3 CR 3a or N, Y 4 CR 4a or N, Y 5 CR 5a or N, Z 1 CR 1b or N, Z2 CR 2b or N, Z 3 CR 3b or N and Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 At least one of them is N, X is -C(R 6 )(R 6a )-, -O-, and -N(R 7 )- Selected from, R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 1a , R 2a , R 3a , R 4a , R 5a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R13 ,-S(O)R 13 -OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 -OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Each R 15a and each R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9Heterocycloalkyl, C 6-10 Arial, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 -OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Arial, -CH2-C6-10 Arial, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 -OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0047] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1CR 1a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 It is N.

[0048] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2 It is N.

[0049] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 3 CR 3a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 3 It is N.

[0050] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 4 It is N.

[0051] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 5 CR 5a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 5 It is N.

[0052] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a That is the case.

[0053] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a is hydrogen and -OR 10 Independently selected from the above. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR 10 In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR 10 And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR 10 And R 10 It is -CH3.

[0054] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 It is N.

[0055] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 2 CR 2b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 2 It is N.

[0056] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 3 It is N.

[0057] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a And Z 1 CR 1b And Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1aY 2 is N, and Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a And Z 1 CR 1b And Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Of these, Y 2 Only N is present. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Only one of them is N. In some embodiments, Y 2 If R is N, 1a and R 5a は-OR 10 In some embodiments, Y 2 If R is N, 1a and R 5a is, -OC 1-6 Alkyl and -OC 1-6 In some embodiments, Y is independently selected from haloalkyl groups. 2 If R is N, 1a and R 5a It is -OCH3.

[0058] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0059] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y1 CR 1a Y 5 CR 5a Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0060] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b And Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 is N, Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b And Z 2 is N, and Z 3 CR 3b In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b And Z 2 CR 2b And, Z 3 It is N.

[0061] In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b are independently selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, and -OR 10 . In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R[[ID=;20]] 2a , R 3a , R 4a , R 1b , R 2b , and R 3b are independently selected from hydrogen, halogen, and C 1-6 alkyl. In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b are hydrogen. In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1b and R 2b are hydrogen, R 3b is -OR 10 , and R 10 is C 1-6 alkyl. In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1b and R 2b are hydrogen, R 3b is -OR 10 , and R 10 is C 1-6 alkyl substituted with one, two, or three halogens.

[0062] In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 1ais hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, or -OR 10 In some embodiments, R 1a is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 alkoxyl, where the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is hydrogen. In some embodiments, R 1a is C 1-6 alkyl. In some embodiments, R 1a is C 1-6 alkoxyl, where the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is C 1-6 alkoxyl. In some embodiments, 1a is -OCF3.

[0063] In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 2a is hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, or -OR 10 In some embodiments, R 2a is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 alkoxyl, where the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 2a is hydrogen. In some embodiments, R 2a is C 1-6 alkyl. In some embodiments, R 2a is C 1-6 alkoxyl, where the alkoxyl is optionally substituted with one, two, or three halogens.

[0064] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 3a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 3a is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl and C 3-6 The cycloalkyl group is optionally substituted. In some embodiments, R 3a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkinyl, or C 2-6 It is an alkynyl. In some embodiments, R 3a is hydrogen. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 In some embodiments, R 3a is C 2-6is alkenyl. In some embodiments, R 3a is C 2-6 alkynyl.

[0065] In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 4a is hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, or -OR 10 . In some embodiments, R 4a is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 4a is hydrogen. In some embodiments, R 4a is C 1-6 alkyl. In some embodiments, R 4a is C 1-6 alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens.

[0066] In some embodiments of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, R 5a is hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, or -OR 10 . In some embodiments, R 5a is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5a is hydrogen. In some embodiments, R 5a is C 1-6 alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5ais C 1-6 It is an alkoxyl. In some embodiments, R 5a is C 1-3 It is an alkoxyl. In some embodiments, R 5a It is -OCH3.

[0067] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1b is hydrogen. In some embodiments, R 1b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R 1b is C 1-6 It is a haloalkyl group.

[0068] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 2b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 2b is hydrogen. In some embodiments, R 2b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R 1b is C 1-6 It is a haloalkyl group.

[0069] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R3b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 3b is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is hydrogen. In some embodiments, R 3b is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is C 1-6 It is an alkoxyl. In some embodiments, R 3b is C 1-3 It is an alkoxyl. In some embodiments, R 3b is C 1-3 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is -OCH3. In some embodiments, R 3b is -OCH2F. In some embodiments, R 3b is -OCF3. In some embodiments, R 3b is -OCHF2. In some embodiments, R 3b It is -OCH2CF3.

[0070] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a They are independently hydrogen, halogen, and C1-6 Selected from alkyl and -OH. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a It is hydrogen.

[0071] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -O-.

[0072] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is hydrogen. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is C 1-6 It is alkyl.

[0073] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0074] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0075] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0076] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl.1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salts or solvates, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrazolyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted imidazolyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted isoxazolyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted oxazolyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 R is an unsubstituted pyridinyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted thiazolyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrimidinyl. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 This is an unsubstituted pyridazinyl compound.

[0077] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0078] [ka] Selected from: In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0079] [ka] Selected from, each has 1, 2, or 3 R 15a It is optionally replaced by R. In some embodiments, 1 teeth

[0080] [ka] In some embodiments, R 1 teeth

[0081] [ka] In some embodiments, R 1 teeth

[0082] [ka] In some embodiments, R 1 teeth

[0083] [ka] In some embodiments, R 1 teeth

[0084] [ka] In some embodiments, R 1 teeth

[0085] [ka] In some embodiments, R 1 teeth

[0086] [ka] In some embodiments, R 1 teeth

[0087] [ka] That is the case.

[0088] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate,

[0089] [ka] teeth,

[0090] [ka] Selected from.

[0091] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is cycloalkyl. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with one, two, or three groups selected from halogens and hydrogen. In some embodiments, R 10 is hydrogen, C 1-6Alkyl, or C 1-6 In some embodiments, R 10 is C 1-6 Alkyl or C 1-6 In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is -CH3. In some embodiments, R 10 is -CH2F. In some embodiments, R 10 is -CHF2. In some embodiments, R 10 is -CH2CF3. In some embodiments, R 10 It is -CF3.

[0092] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 11 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 11 is hydrogen. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 11 is C 1-6 It is alkyl.

[0093] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 12 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 12 is hydrogen. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 12 is C 1-6 It is alkyl.

[0094] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 Alkyl, C 1-6Haloalkyl, or C 3-6 It is a cycloalkyl compound. In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, R 13 C 1-6 Alkyl or C 1-6 It is a haloalkyl group.

[0095] In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0096] In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (I), each R15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (I), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0097] In some embodiments, formula (Ia)

[0098] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, Y 2 CR 2a or N, Y 3 CR 3a or N, Y 4 CR 4a or N, Z 1 CR 1b or N, Z 2 CR 2b or N, Z 3 CR 3b or N and Y 2 , Y 3 , Y 4 , Z 1 , Z 2 , and Z 3 At least one of them is N, X is -C(R 6 )(R 6a )-, -O-, and -N(R 7 )- Selected from, R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 1a , R 2a , R 3a , R 4a , R 5a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10)(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Each R 15a and each R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12)S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0099] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a and R 5a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a and R 5a These are independently hydrogen and -OR 10 Selected from: In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a and R 5a は-OR 10 In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a and R 5a は-OR 10And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a and R 5a は-OR 10 And R 10 It is -CH3.

[0100] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0101] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 It is N.

[0102] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 3 CR 3a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 3 It is N.

[0103] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 4 CR 4a In some embodiments of the compound of formula (I), or its pharmaceutically acceptable salt or solvate, Y 4 It is N.

[0104] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0105] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 is N, Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 is N, and Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 CR 2b And, Z 3 It is N.

[0106] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 1 It is N.

[0107] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 2 CR 2b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 2 It is N.

[0108] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Z 3 It is N.

[0109] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 2 is N, and Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Of these, Y2 Only N is present. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Only one of them is N. In some embodiments, Y 2 If R is N, 1a and R 5a は-OR 10 In some embodiments, Y 2 If R is N, 1a and R 5a is, -OC 1-6 Alkyl and -OC 1-6 In some embodiments, Y is independently selected from haloalkyl groups. 2 If R is N, 1a and R 5a It is -OCH3.

[0110] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b These are independently hydrogen, halogen, and C 1-6 Selected from alkyl groups. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 2a, R 3a , R 4a , R 1b , R 2b , and R 3b is hydrogen. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1b and R 2b is hydrogen, R 3b は-OR 10 And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1b and R 2b is hydrogen, R 3b は-OR 10 And R 10 C is substituted with one, two, or three halogens. 1-6 It is alkyl.

[0111] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 1a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is hydrogen. In some embodiments, R 1a is C 1-6 It is alkyl. In some embodiments, R 1a is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is C 1-6 It is an alkoxyl. In some embodiments, 1a It is -OCF3.

[0112] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 2a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 2a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 2a is hydrogen. In some embodiments, R 2a is C 1-6 It is alkyl. In some embodiments, R 2a is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0113] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 3a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 3a is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-6 Alkenil, C 2-6 Alkinyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl and C 3-6 The cycloalkyl group is optionally substituted. In some embodiments, R 3a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkinyl, or C 2-6 It is an alkynyl. In some embodiments, R 3a is hydrogen. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 In some embodiments, R 3a is C 2-6 It is an alkenyl. In some embodiments, R 3a is C 2-6 It is alkinyl.

[0114] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 4a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 4a is hydrogen. In some embodiments, R 4a is C 1-6 It is alkyl. In some embodiments, R 4a is C1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0115] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 5a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 5a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5a is hydrogen. In some embodiments, R 5a is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5a is C 1-6 It is an alkoxyl. In some embodiments, R 5a is C 1-3 It is an alkoxyl. In some embodiments, R 5a It is -OCH3.

[0116] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1b is hydrogen. In some embodiments, R 1b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R1b is C 1-6 It is a haloalkyl group.

[0117] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 2b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 2b is hydrogen. In some embodiments, R 2b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R 1b is C 1-6 It is a haloalkyl group.

[0118] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 3b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 3b is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is hydrogen. In some embodiments, R 3b is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is C 1-6 It is an alkoxyl. In some embodiments, R 3b is C 1-3 It is an alkoxyl. In some embodiments, R 3b is C1-3 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is -OCH3. In some embodiments, R 3b is -OCH2F. In some embodiments, R 3b is -OCF3. In some embodiments, R 3b is -OCHF2. In some embodiments, R 3b It is -OCH2CF3.

[0119] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Selected from alkyl and -OH. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a It is hydrogen.

[0120] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -O-.

[0121] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7is hydrogen. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is C 1-6 It is alkyl.

[0122] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0123] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0124] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0125] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salts or solvates, R 1 is an unsubstituted pyrazolyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted imidazolyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1is an unsubstituted isoxazolyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted oxazolyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyridinyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted thiazolyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrimidinyl. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 This is an unsubstituted pyridazinyl compound.

[0126] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0127] [ka] Selected from.

[0128] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0129] [ka] That is the case.

[0130] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0131] [ka] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0132] [ka] Selected from, each has 1, 2, or 3 R 15a It is optionally replaced by R. In some embodiments, 1 teeth

[0133] [ka] In some embodiments, R 1 teeth

[0134] [ka] In some embodiments, R 1 teeth

[0135] [ka] In some embodiments, R 1 teeth

[0136] [ka] In some embodiments, R 1 teeth

[0137] [ka] In some embodiments, R 1 teeth

[0138] [ka] In some embodiments, R 1 teeth

[0139] [ka] In some embodiments, R 1 teeth

[0140] [ka] That is the case.

[0141] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate,

[0142] [ka] teeth,

[0143] [ka] Selected from.

[0144] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is cycloalkyl. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with one, two, or three groups selected from halogens and hydrogen. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, or C 1-6 In some embodiments, R 10 is C 1-6 Alkyl or C1-6 In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is -CH3. In some embodiments, R 10 is -CH2F. In some embodiments, R 10 is -CHF2. In some embodiments, R 10 is -CH2CF3. In some embodiments, R 10 It is -CF3.

[0145] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 11 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 11 is hydrogen. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 11 is C 1-6 It is alkyl.

[0146] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 12 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 12 is hydrogen. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 12 is C 1-6 It is alkyl.

[0147] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6It is a cycloalkyl compound. In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, R 13 C 1-6 Alkyl or C 1-6 It is a haloalkyl group.

[0148] In some embodiments of the compound of formula (Ia), or its pharmaceutically acceptable salt or solvate, each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0149] In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (Ia), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0150] In some embodiments, formula (I')

[0151] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, Y 1 CR 1a or N, Y 2 CR 2a or N, Y 3 CR 3a or N, Y 4 CR 4a or N, Y 5 CR 5a or N, Z 1 CR 1b or N, Z 2 CR 2b or N, Z 3 CR 3b or N, X is either -O- or -S-, or X is -C(R 6 )(R 6a )- and -N(R 7 )- Selected from, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z2 , and Z 3 At least one of them is N, R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 1a , R 2a , R 3a , R 4a , R 5a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Each R 15a and each R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0152] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -O-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -S-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -O- or -S-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and Y 1 , Y 2 , Y 3 , Y4 , Y 5 , Z 1 , Z 2 , and Z 3 At least one of them is N. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 At least one of them is N.

[0153] In some embodiments, formula (I')

[0154] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, Y 1 CR 1a or N, Y 2 CR 2a or N, Y 3 CR 3a or N, Y 4 CR 4a or N, Y 5 CR 5a or N, Z 1 CR 1b or N, Z 2 CR 2b or N, Z 3 CR 3b or N, X is -O-, R 1 R 15aC is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 1a , R 2a , R 3a , R 4a , R 5a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Each R 15a and each R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0155] In some embodiments, the compound of formula (I') has the structure of formula (Ia).

[0156] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -O-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -S-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -C(R6 )(R 6a )-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-is.

[0157] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 It is N.

[0158] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 It is N.

[0159] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 3 CR 3a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 3 It is N.

[0160] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 4 CR 4a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 4 It is N.

[0161] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 5 CR 5aIn some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 5 It is N.

[0162] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a That is the case.

[0163] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a is hydrogen and -OR 10 Independently selected from the above. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR 10 In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR10 And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a And R 1a and R 5a は-OR 10 And R 10 It is -CH3.

[0164] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0165] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y2 is N, and Y 3 CR 3a Y 4 CR 4a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 CR 2a Y 3 is N, and Y 4 CR 4a In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 is N, and Y 3 CR 3a Y 4 is N. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 5 CR 5a Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a That is the case.

[0166] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 is N, Z 2 CR2b And, Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 is N, and Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b Z 2 CR 2b And, Z 3 It is N.

[0167] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 CR 1b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 1 It is N.

[0168] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 2 CR 2b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 2 It is N.

[0169] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Z 3 It is N.

[0170] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1CR 1a Y 2 CR 2a Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 CR 1a Y 2 is N, and Y 3 CR 3a Y 4 CR 4a Y 5 CR 5a Z 1 CR 1b Z 2 CR 2b And, Z 3 CR 3b In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Of these, Y 2 Only N. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Z 1 , Z 2 , and Z 3 Only one of them is N. In some embodiments, Y 2 If R is N, 1aand R 5a は-OR 10 In some embodiments, Y 2 If R is N, 1a and R 5a is, -OC 1-6 Alkyl and -OC 1-6 In some embodiments, Y is independently selected from haloalkyl groups. 2 If R is N, 1a and R 5a It is -OCH3.

[0171] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b These are independently hydrogen, halogen, and C 1-6 Selected from alkyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 2a , R 3a , R 4a , R 1b , R 2b , and R 3b is hydrogen. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1b and R 2b is hydrogen, R 3b は-OR 10 And R 10 is C 1-6It is alkyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1b and R 2b is hydrogen, R 3b は-OR 10 And R 10 C is substituted with one, two, or three halogens. 1-6 It is alkyl.

[0172] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 1a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is hydrogen. In some embodiments, R 1a is C 1-6 It is alkyl. In some embodiments, R 1a is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 1a is C 1-6 It is an alkoxyl. In some embodiments, 1a It is -OCF3.

[0173] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 2a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 2a is hydrogen, C 1-6 Alkyl, C 1-6Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 2a is hydrogen. In some embodiments, R 2a is C 1-6 It is alkyl. In some embodiments, R 2a is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0174] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 3a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 3a is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl and C 3-6 The cycloalkyl group is optionally substituted. In some embodiments, R 3a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-6 Alkinyl, or C 2-6 It is an alkynyl. In some embodiments, R 3a is hydrogen. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 It is alkyl. In some embodiments, R 3a is C 1-6 In some embodiments, R 3a is C 2-6 It is an alkenyl. In some embodiments, R 3a is C 2-6 It is alkinyl.

[0175] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 4a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 4a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 4a is hydrogen. In some embodiments, R 4a is C 1-6 It is alkyl. In some embodiments, R 4a is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0176] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 5a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10In some embodiments, R 5a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5a is hydrogen. In some embodiments, R 5a is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 5a is C 1-6 It is an alkoxyl. In some embodiments, R 5a is C 1-3 It is an alkoxyl. In some embodiments, R 5a It is -OCH3.

[0177] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1b is hydrogen. In some embodiments, R 1b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R 1b is C 1-6 It is a haloalkyl group.

[0178] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 2b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15bIt is optionally replaced with one, two, or three bases selected from. In some embodiments, R 2b is hydrogen. In some embodiments, R 2b is a halogen. In some embodiments, R 1b is C 1-6 It is alkyl. In some embodiments, R 1b is C 1-6 It is a haloalkyl group.

[0179] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 3b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 3b is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is hydrogen. In some embodiments, R 3b is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is C 1-6 It is an alkoxyl. In some embodiments, R 3b is C 1-3 It is an alkoxyl. In some embodiments, R 3b is C 1-3 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 3b is -OCH3. In some embodiments, R 3b is -OCH2F. In some embodiments, R 3b is -OCF3. In some embodiments, R 3bis -OCHF2. In some embodiments, R 3b It is -OCH2CF3.

[0180] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Selected from alkyl and -OH. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a It is hydrogen.

[0181] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -O-.

[0182] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is hydrogen. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is C 1-6 It is alkyl.

[0183] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution.1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0184] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C1-6 Haloalkyl and -OR 10 Selected from.

[0185] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15aSubstituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0186] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 It is a heteroaryl compound, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are unsubstituted. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (I') or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrazolyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted imidazolyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted isoxazolyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted oxazolyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 R is an unsubstituted pyridinyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1is an unsubstituted thiazolyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrimidinyl. In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 This is an unsubstituted pyridazinyl compound.

[0187] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0188] [ka] Selected from: In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0189] [ka] Selected from, each has 1, 2, or 3 R 15a It is optionally replaced by R. In some embodiments, 1 teeth

[0190] [ka] In some embodiments, R 1 teeth

[0191] [ka] In some embodiments, R 1 teeth

[0192] [ka] In some embodiments, R 1 teeth

[0193] [ka] In some embodiments, R 1 teeth

[0194] [ka] In some embodiments, R 1 teeth

[0195] [ka] In some embodiments, R 1 teeth

[0196] [ka] In some embodiments, R 1 teeth

[0197] [ka] That is the case.

[0198] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate,

[0199] [ka] teeth,

[0200] [ka] Selected from.

[0201] In some embodiments of the compound of formula (I'), or its pharmaceutically acceptable salt or solvate, R 10 is hydrogen, C 1-6Alkyl, C 1-6 Haloalkyl, or C 3-6 Cycloalkyl. In some embodiments, R 10 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 3-6 cycloalkyl, and C 1-6 alkyl and C 3-6 cycloalkyl are optionally substituted with one, two, or three groups selected from halogen, hydrogen. In some embodiments, R 10 is hydrogen, C 1-6 alkyl, or C 1-6 haloalkyl. In some embodiments, R 10 is C 1-6 alkyl or C 1-6 haloalkyl. In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is -CH3. In some embodiments, R 10 is -CH2F. In some embodiments, R 10 is -CHF2. In some embodiments, R 10 is -CH2CF3. In some embodiments, R 10 is -CF3.

[0202] In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 11 is hydrogen, C 1-6 alkyl, and C 1-6 haloalkyl. In some embodiments, R 11 is hydrogen. In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 11 is C 1-6 alkyl.

[0203] In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 12 is hydrogen, C1-6 alkyl, and C 1-6 is haloalkyl. In some embodiments, R 12 is hydrogen. In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 12 is C 1-6 alkyl.

[0204] In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 13 is C 1-6 alkyl, C 1-6 haloalkyl, or C 3-6 cycloalkyl. In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, R 13 is C 1-6 alkyl or C 1-6 haloalkyl.

[0205] In some embodiments of the compound of formula (I’), or a pharmaceutically acceptable salt or solvate thereof, each R 15a , each R 15b , and each R 15c is independently halogen, oxo, -CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, -CH2-C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH2-C 2-9 heterocycloalkyl, C 6-10 aryl, -CH2-C 6-10 aryl, C 1-9 heteroaryl, -CH2-C 1-9 heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ). In some embodiments of the compound of formula (I’), each R15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0206] In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (I'), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0207] In some embodiments of compounds of formula (I), (I'), or (Ia), or their pharmaceutically acceptable salts or solvates, Z 1 CR 1b Z 2 CR 2b Z 3 CR 3b And each R 1a and each R 5a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from, each R 2a , each R 3a , each R 4a , each R 1b , each R 2b , and each R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from, R10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, or C 2-9 It is a heterocycloalkyl compound. In some embodiments of the compounds of formula (I), (I'), or (Ia), or their pharmaceutically acceptable salts or solvates, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compounds of formula (I), (I'), or (Ia), or their pharmaceutically acceptable salts or solvates, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compounds of formula (I), (I'), or (Ia), or their pharmaceutically acceptable salts or solvates, R 1 These are pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Selective substitution with one, two, or three groups selected from. In some embodiments of the compounds of formula (I), (I'), or (Ia), or their pharmaceutically acceptable salts or solvates, R 1 teeth,

[0208] [ka] Selected from: A compound of formula (I), (I'), or (Ia), or a pharmaceutically acceptable salt or solvate thereof, in some embodiments, R 10 C 1-6 Alkyl or C 1-6 It is a haloalkyl group.

[0209] In some embodiments, formula (II)

[0210] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, X is -C(R 6 )(R 6a )-, -O-, and -N(R 7 )- Selected from, R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 8a , R 8b , R 8c , R 8d , R 8e , R 9b , and R 9c These are, independently, hydrogen, halogen, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 9a C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 14 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10)(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl and C 3-6 Cycloalkyl is R 15c Substituted with one, two, or three groups selected from C 2-6 Alkenil, C 2-6 Alkinyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15d It is optionally replaced by one, two, or three elements selected from R 9a and R 9b When combined, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, or C 2-9 Forms a heteroaryl compound, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 2-9 Heteroaryls are R 15e It is optionally replaced by one, two, or three elements selected from the following: R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R14 Hydrogen and C are independent of each other. 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 2-6 Alkenil, C 2-6 Alkinyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Each R 15a , each R 15b , each R 15c , each R 15d , and each R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0211] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e These are independently hydrogen and -OR 10Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 And R 10 It is -CH3.

[0212] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8a is hydrogen. In some embodiments, R 8a is C 1-6 It is alkyl. In some embodiments, R 8a is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8a is C 1-6 It is an alkoxyl. In some embodiments, R 8a It is -OCF3.

[0213] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8e Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8e is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8e is hydrogen. In some embodiments, R 8e is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8e is C 1-6 It is an alkoxyl. In some embodiments, R 8e is C 1-3 It is an alkoxyl. In some embodiments, R 8e It is -OCH3.

[0214] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8b , R 8c , R 8d , and R 9c They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8b , R 8c , R 8d , and R 9c These are independently hydrogen, halogen, and C 1-6 Selected from alkyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8b , R 8c , R8d , and R 9c It is hydrogen.

[0215] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8b is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8b is hydrogen. In some embodiments, R 8b is C 1-6 It is alkyl. In some embodiments, R 8b is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0216] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8c Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 8c is hydrogen, halogen, C1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl and C 3-6 The cycloalkyl group is optionally substituted. In some embodiments, R 8c is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkinyl, or C 2-6 It is an alkynyl. In some embodiments, R 8c is hydrogen. In some embodiments, R 8c is C 1-6 It is alkyl. In some embodiments, R 8c is C 1-6 It is alkyl. In some embodiments, R 8c is C 1-6 In some embodiments, R 8c is C 2-6 It is an alkenyl. In some embodiments, R 8c is C 2-6 It is alkinyl.

[0217] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 8d Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8d is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8d is hydrogen. In some embodiments, R 8d is C 1-6is alkyl. In some embodiments, R 8d is C 1-6 alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens.

[0218] In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9c is hydrogen, halogen, C 1-6 alkyl, or C 1-6 haloalkyl, and the C 1-6 alkyl is optionally substituted with one, two, or three groups selected from R 15b . In some embodiments, R 9c is hydrogen. In some embodiments, R 9c is halogen. In some embodiments, R 9c is C 1-6 alkyl. In some embodiments, R 9c is C 1-6 haloalkyl.

[0219] In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9b is selected from hydrogen, halogen, and C 1-6 alkyl. In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9b is hydrogen. In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9b is halogen. In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9b is C 1-6 alkyl. In some embodiments of the compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, R 9b is -CH3.

[0220] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 9b is hydrogen. In some embodiments, R 9b is a halogen. In some embodiments, R 9b is C 1-6 It is alkyl. In some embodiments, R 9b is C 1-6 It is a haloalkyl group.

[0221] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 And R 14 is C 1-6 It is a haloalkyl compound. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 And R 14 is -CF3. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 And R 14 It is -CHF2.

[0222] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a R 15c C is replaced by one, two, or three groups selected from the above. 3-6It is a cycloalkyl compound. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a R 15c C is replaced by one, two, or three groups selected from the above. 3-6 It is cycloalkyl, R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Selected from haloalkyls. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a R 15c C is replaced by one, two, or three groups selected from the above. 3-6 It is cycloalkyl, R 15c These are all halogens.

[0223] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a is C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 14 In some embodiments, R 9a is C 1-6 Alkyl, C 1-6 Haloalkyl, or -OC 1-6 In some embodiments, R 9a ha-OC 1-6 In some embodiments, R 9a ha-OC 1-6 In some embodiments, R 9a It is -OCH2F.

[0224] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a and R 9b When combined, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, or C 2-9 Forms a heteroaryl compound, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, and C 2-9 Heteroaryls are R 15e It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a and R 9b When combined, R 15e C is optionally replaced by one, two, or three elements selected from the above. 2-9 It forms a heterocycloalkyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a and R 9b When combined, halogen, C 1-6 Alkyl, and C 1-6 C is optionally substituted with one, two, or three groups selected from haloalkyl groups. 2-9 It forms a heterocycloalkyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is cycloalkyl. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with one, two, or three groups selected from halogens and hydrogen. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, or C 1-6 In some embodiments, R 10 is C 1-6 Alkyl or C 1-6 In some embodiments, R 10 is hydrogen. In some embodiments, R10 is -CH3. In some embodiments, R 10 is -CH2F. In some embodiments, R 10 is -CHF2. In some embodiments, R 10 is -CH2CF3. In some embodiments, R 10 It is -CF3.

[0225] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 9a and R 9b When combined, they form a ring with 5 to 7 members. In some embodiments, R 9a and R 9b When combined, they form a 6-membered ring. In some embodiments, R 9a and R 9b When combined, they form a cycloalkyl group. In some embodiments, R 9a and R 9b When combined, they form a heterocycloalkyl. In some embodiments, R 9a and R 9b When combined, they form a ring containing one or two oxygen atoms and zero to two nitrogen atoms. In some embodiments, R 9a and R 9b When combined, they form a ring containing one oxygen atom.

[0226] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate,

[0227] [ka] teeth,

[0228] [ka] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate,

[0229] [ka] teeth,

[0230] [ka] That is the case.

[0231] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 11 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 11 is hydrogen. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 11 is C 1-6 It is alkyl.

[0232] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 12 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 12 is hydrogen. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 12 is C 1-6 It is alkyl.

[0233] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 Haloalkyl, C 1-6 Alkyl, or C 3-6It is a cycloalkyl compound. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 It is alkyl.

[0234] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 14 is hydrogen, C 1-6 Haloalkyl, or C 3-6 It is cycloalkyl. In some embodiments, R 14 is hydrogen or C 1-6 In some embodiments, R 14 is C 1-6 In some embodiments, R 14 is hydrogen. In some embodiments, R 14 is -CH2F. In some embodiments, R 14 is -CH2CF3. In some embodiments, R 14 It is -CF3.

[0235] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13, or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0236] In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (II), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0237] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Selected from alkyl and -OH. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -C(R 6 )(R 6a )- and R 6 and R 6a It is hydrogen.

[0238] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -O-.

[0239] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is hydrogen. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is C 1-6 It is alkyl.

[0240] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0241] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0242] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0243] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 It is a heteroaryl compound, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are unsubstituted. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 The compounds are heteroaryl, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are unsubstituted. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrazolyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted imidazolyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted isoxazolyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted oxazolyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 R is an unsubstituted pyridinyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted thiazolyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrimidinyl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 This is an unsubstituted pyridazinyl compound.

[0244] In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0245] [ka] Selected from: In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0246] [ka] Selected from, each has 1, 2, or 3 R 15a It is optionally replaced by R. In some embodiments, 1 teeth

[0247] [ka] In some embodiments, R 1 teeth

[0248] [ka] In some embodiments, R 1 teeth

[0249] [ka] In some embodiments, R 1 teeth

[0250] [ka] In some embodiments, R 1 teeth

[0251] [ka] In some embodiments, R 1 teeth

[0252] [ka] In some embodiments, R 1teeth

[0253] [ka] That is the case.

[0254] In some embodiments, formula (III)

[0255] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, X is -O- and -N(R 7 )- Selected from, R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Optionally substituted with one, two, or three groups selected from heteroaryls, R 8a , R 8b , R 8c , R 8d , R 8e , R 9b , and R 9c These are, independently, hydrogen, halogen, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13, and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: R 9a is hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, and -OR 14 Selected from, R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, and C 1-6 Selected from haloalkyl groups, R 13 Each is independent of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 14 is C 1-6 Alkyl and C 3-6 Selected from cycloalkyl groups, and also, Each R 15a and each R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(=O)(=NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0256] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e They are independently hydrogen, halogen, and C 1-6Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e These are independently hydrogen and -OR 10 Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 And R 10 is C 1-6 It is alkyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a and R 8e は-OR 10 And R 10 It is -CH3.

[0257] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8a Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8a is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8a is hydrogen. In some embodiments, R 8a is C 1-6 It is alkyl. In some embodiments, R 8a is C 1-6It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8a is C 1-6 It is an alkoxyl. In some embodiments, R 8a It is -OCF3.

[0258] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8e Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8e is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8e is hydrogen. In some embodiments, R 8e is C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8e is C 1-6 It is an alkoxyl. In some embodiments, R 8e is C 1-3 It is an alkoxyl. In some embodiments, R 8e It is -OCH3.

[0259] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8b , R 8c , R 8d , and R 9c They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R8b , R 8c , R 8d , and R 9c These are independently hydrogen, halogen, and C 1-6 Selected from alkyl groups. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8b , R 8c , R 8d , and R 9c It is hydrogen.

[0260] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8b is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8b is hydrogen. In some embodiments, R 8b is C 1-6 It is alkyl. In some embodiments, R 8b is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0261] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8c Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 8c is hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl and C 3-6 The cycloalkyl group is optionally substituted. In some embodiments, R 8c is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkinyl, or C 2-6 It is an alkynyl. In some embodiments, R 8c is hydrogen. In some embodiments, R 8c is C 1-6 It is alkyl. In some embodiments, R 8c is C 1-6 It is alkyl. In some embodiments, R 8c is C 1-6 In some embodiments, R 8c is C 2-6 It is an alkenyl. In some embodiments, R 8c is C 2-6 It is alkinyl.

[0262] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 8d Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments, R 8d is hydrogen, C1-6 Alkyl, C 1-6 Haloalkyl, or C 1-6 It is an alkoxyl, and the alkoxyl is optionally substituted with one, two, or three halogens. In some embodiments, R 8d is hydrogen. In some embodiments, R 8d is C 1-6 It is alkyl. In some embodiments, R 8d is C 1-6 It is an alkoxyl, and the alkoxyl can be optionally substituted with one, two, or three halogens.

[0263] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9c is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 9c is hydrogen. In some embodiments, R 9c is a halogen. In some embodiments, R 9c is C 1-6 It is alkyl. In some embodiments, R 9c is C 1-6 It is a haloalkyl group.

[0264] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9b These are hydrogen, halogens, and C 1-6 Selected from alkyl groups. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9b is hydrogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9bis a halogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9b is C 1-6 It is alkyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9b It is -CH3.

[0265] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9b is hydrogen, halogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is R 15b It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 9b is hydrogen. In some embodiments, R 9b is a halogen. In some embodiments, R 9b is C 1-6 It is alkyl. In some embodiments, R 9b is C 1-6 It is a haloalkyl group.

[0266] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 And R 14 is C 1-6 It is alkyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14 And R 14 is -CH3. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a は-OR 14And R 14 is C 3-6 It is cycloalkyl. In some embodiments, R 9a It is -OCH2F.

[0267] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a is C 1-6 Alkyl, C 3-6 Cycloalkyl, or -OR 14 In some embodiments, R 9a C 1-6 Alkyl, C 1-6 Cycloalkyl, or C 1-6 It is an alkoxyl. In some embodiments, R 9a is C 1-6 It is an alkoxyl. In some embodiments, R 9a is C 1-3 It is an alkoxyl.

[0268] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a is hydrogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a is C 1-6 It is alkyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 9a is C 3-6 It is a cycloalkyl compound. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, X is -O-.

[0269] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )-. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7is hydrogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, X is -N(R 7 )- and R 7 is C 1-6 It is alkyl.

[0270] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is cycloalkyl. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, or C 3-6 It is a cycloalkyl, C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with one, two, or three groups selected from halogens and hydrogen. In some embodiments, R 10 is hydrogen, C 1-6 Alkyl, or C 1-6 In some embodiments, R 10 is C 1-6 Alkyl or C 1-6 In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is -CH3. In some embodiments, R 10 is -CH2F. In some embodiments, R 10 is -CHF2. In some embodiments, R 10 is -CH2CF3. In some embodiments, R 10 It is -CF3.

[0271] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 11 is hydrogen, C 1-6 Alkyl, and C 1-6In some embodiments, R 11 is hydrogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 11 is C 1-6 It is alkyl.

[0272] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 12 is hydrogen, C 1-6 Alkyl, and C 1-6 In some embodiments, R 12 is hydrogen. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 12 is C 1-6 It is alkyl.

[0273] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 Haloalkyl, C 1-6 Alkyl, or C 3-6 It is a cycloalkyl compound. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 It is alkyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 13 is C 1-6 It is a haloalkyl group.

[0274] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 14 is C 1-6 Alkyl or C 3-6 It is cycloalkyl. In some embodiments, R 14 is C 1-6 It is alkyl. In some embodiments, R 14 is C 3-6It is cycloalkyl. In some embodiments, R 14 It is -CH3.

[0275] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, each R 15a and each R 15b These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (III), each R 15a and each R 15b These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (III), each R 15a and each R 15b These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (III), each R 15a and each R 15bThey are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0276] In some embodiments of the compound of formula (III), each R 15a and each R 15b They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (III), each R 15a and each R 15b These are independent, -OR 10 That is the case.

[0277] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (II), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0278] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0279] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a It is substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0280] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 The heteroaryl compounds are pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl, which are unsubstituted. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl. 1-9 It is a heteroaryl compound, and pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and pyridinyl are unsubstituted. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrazolyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted imidazolyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1is an unsubstituted isoxazolyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted oxazolyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyridinyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted thiazolyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 is an unsubstituted pyrimidinyl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 This is an unsubstituted pyridazinyl compound.

[0281] In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0282] [ka] Selected from: In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1 teeth,

[0283] [ka] Selected from, each has 1, 2, or 3 R 15a It is optionally replaced by R. In some embodiments, 1 teeth

[0284] [ka] In some embodiments, R 1 teeth

[0285] [ka] In some embodiments, R 1 teeth

[0286] [ka] In some embodiments, R 1 teeth

[0287] [ka] In some embodiments, R 1 teeth

[0288] [ka] In some embodiments, R 1 teeth

[0289] [ka] In some embodiments, R 1 teeth

[0290] [ka] That is the case.

[0291] Any combination of the above groups is contemplated herein for various variables. Throughout the specification, the groups and their substituents are selected by those skilled in the art to provide stable moieties and compounds.

[0292] In some embodiments,

[0293] [ka]

[0294] [ka] Compounds selected from, or pharmaceutically acceptable salts or solvates thereof, are provided herein.

[0295] In some embodiments, compounds, or pharmaceutically acceptable salts or solvates thereof, are provided herein, and the compounds are selected from the compounds in Table 1A.

[0296] [Table 1-1]

[0297] [Table 1-2]

[0298] [Table 1-3]

[0299] [Table 1-4]

[0300] [Table 1-5]

[0301] [Table 1-6]

[0302] In some embodiments, formula (IV)

[0303] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, R 2 C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, and each is R 15c It is optionally replaced by one, two, three, or four elements selected from the following: Z 1 CR 1b or N, Z 2 CR 2b or N, Z 3 CR 3b or N, R 1 C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, and each is R 15a It is optionally replaced by one, two, or three elements selected from the following: R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: Alternatively, R 2b and R 3b They become one, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 Forms a heteroaryl compound, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15e It is optionally replaced by one, two, three, or four elements selected from the following: Each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10)(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on adjacent carbon atoms 15e They combine to form a C2 alkenylene, Alternatively, two R atoms on the same atom 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 They form heteroaryls, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11)-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 Each of them is independently of hydrogen and C 1-6 Alkyl, or C 1-6 It is a haloalkyl, R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, or C 1-6 It is a haloalkyl, and also R 13Each of them is independently of hydrogen and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryl groups.

[0304] In some embodiments of the compound of formula (IV), R 2 is C 6-10 Aryl or C 1-9 It is a heteroaryl, and each is R 15c It is optionally replaced by one, two, three, or four elements selected from the set.

[0305] In some embodiments of the compound of formula (IV), R 2 R 15c C is optionally replaced by one, two, three, or four elements selected from the above. 1-9 It is a heteroaryl compound.

[0306] In some embodiments of the compound of formula (IV), R 2 R 15c It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, three, or four groups selected from the above.

[0307] In some embodiments of the compound of formula (IV), R 2 R 15c It is a six-membered heteroaryl molecule that is optionally substituted with one, two, three, or four groups selected from the above.

[0308] In some embodiments of the compound of formula (IV), R 2 R 15c It is a pyridinyl molecule that is optionally substituted with one, two, three, or four groups selected from the following.

[0309] In some embodiments of the compound of formula (IV), R 2 R 15c It is a phenyl molecule that is optionally substituted with one, two, three, or four groups selected from the following.

[0310] In embodiments of the compound of formula (IV), R 2 teeth,

[0311] [ka] That is the case.

[0312] In some embodiments of the compound of formula (IV), Z 1 CR 1b Z 2 CR 2b Z 3 CR 3b In some embodiments of the compound of formula (IV), Z 1 is N, Z 2 CR 2b Z 3 CR 3b In some embodiments of the compound of formula (IV), Z 1 CR 1b Z 2 is N, Z 3 CR 3b In some embodiments of the compound of formula (IV), Z 1 CR1b Z 2 CR 2b Z 3 It is N.

[0313] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) and C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the set.

[0314] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -OR 10 , -SR 10 , or -SF5, C 1-6 Alkyl, C 3-6 Cycloalkyl, and C 2-9 Heterocycloalkyl is R 15bIt is optionally replaced by one, two, or three elements selected from the set.

[0315] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b They are independently hydrogen, halogen, and C 3-6 Cycloalkyl, -OR 10 , -SR 10 , or -SF5, C 3-6 Cycloalkyl is R 15b It is optionally replaced by one, two, or three elements selected from the set.

[0316] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b These are independently hydrogen, halogen, and -OR 10 , -SR 10 , or -SF5.

[0317] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b These are independently hydrogen or -OR 10 That is the case.

[0318] In some embodiments of the compound of formula (IV), R 1b , R 2b , and R 3b It is hydrogen.

[0319] In some embodiments of the compound of formula (IV), R 1b It is hydrogen.

[0320] In some embodiments of the compound of formula (IV), R 2b and R 3b They become one, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 Forms a heteroaryl compound, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15e It is optionally replaced by one, two, three, or four elements selected from the set.

[0321] In some embodiments of the compound of formula (IV), R 2b and R 3b They become one, C 3-6 Cycloalkyl or C 2-9 Forms a heterocycloalkyl group, C 3-6 Cycloalkyl and C 2-9 Heterocycloalkyl is R 15e It is optionally replaced by one, two, three, or four elements selected from the set.

[0322] In some embodiments of the compound of formula (IV), R 2b and R 3b They become one, R 15e C is optionally replaced by one, two, three, or four elements selected from the above. 2-9 It forms a heterocycloalkyl group.

[0323] In some embodiments of the compound of formula (IV), R 2b and R 3b They become one, R 15e C is optionally replaced by one, two, three, or four elements selected from the above. 2-6 It forms a heterocycloalkyl group.

[0324] In some embodiments of the compound of formula (IV), R 2b and R 3b They become one, R 15e C is optionally replaced by one, two, three, or four elements selected from the above. 6-9 It forms a heterocycloalkyl group.

[0325] In some embodiments of the compound of formula (IV), R2b and R 3b These together form a 5-7 membered heterocycloalkyl group containing one or two heteroatoms selected from O and N. In some embodiments of the compound of formula (IV), R 2b and R 3b These combine to form a six-membered heterocycloalkyl group containing one heteroatom, which is oxygen.

[0326] In some embodiments of the compound of formula (IV), R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 )

[0327] In some embodiments of the compound of formula (IV), R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0328] In some embodiments of the compound of formula (IV), R 15e These are, independently, halogen, oxo, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0329] In some embodiments of the compound of formula (IV), two R on adjacent carbons 15e These combine to form a C2 alkenylene.

[0330] In some embodiments of the compound of formula (IV), two R on the same atom 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0331] In some embodiments of the compound of formula (IV), two R on the same atom 15e These are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0332] In some embodiments of the compound of formula (IV), two R on the same atom 15e They become one, C 3-6 It forms a cycloalkyl group.

[0333] In some embodiments of the compound of formula (IV), two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl or C 2-9They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0334] In some embodiments of the compound of formula (IV), two R atoms on different atoms 15e These are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0335] In some embodiments of the compound of formula (IV), two R atoms on different atoms 15e They become one, C 3-6 It forms a cycloalkyl group.

[0336] In some embodiments of the compound of formula (IV), R 2b and R 3b They became one,

[0337] [ka] It forms.

[0338] In some embodiments of the compound of formula (IV), R 1 is C 6-10 Aryl or C 1-9 It is a heteroaryl, and each is R 15aIt is optionally replaced by one, two, or three elements selected from the set.

[0339] In some embodiments of the compound of formula (IV), R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl compound.

[0340] In some embodiments of the compound of formula (IV), R 1 R 15a It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0341] In some embodiments of the compound of formula (IV), R 1 R 15a It is a five-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0342] In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (III), or its pharmaceutically acceptable salt or solvate, R 1It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0343] In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0344] In some embodiments of the compound of formula (IV), R 1 C is selected from pyrazolyl and thiazolyl. 1-9 It is a heteroaryl compound, and pyrazolyl and thiazolyl are R 15a It is optionally replaced by one, two, or three elements selected from the set.

[0345] In some embodiments of the compound of formula (IV), R 1 R 15a Thiazolyl is optionally substituted with one, two, or three groups selected from the following.

[0346] In some embodiments of the compound of formula (IV), R1 R 15a It is a pyrazolyl compound that is optionally substituted with one, two, or three groups selected from the following.

[0347] In some embodiments of the compound of formula (IV), R 1 teeth

[0348] [ka] That is the case.

[0349] In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), each R 15a, each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0350] In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15cC 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (IV), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0351] In some embodiments of the compound of formula (IV), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15a Each is independent of the other, -OR 10 That is the case.

[0352] In some embodiments of the compound of formula (IV), R 15bThese are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0353] In some embodiments of the compound of formula (IV), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6Haloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15b Each is independent of the other, -OR 10 That is the case.

[0354] In some embodiments of the compound of formula (IV), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (IV), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0355] In some embodiments of the compound of formula (IV), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each is independent of C 1-6 Alkyl, C 3-10Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (IV), R 15c Each is independent of the other, -OR 10 That is the case.

[0356] In some embodiments, formula (V)

[0357] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, R 2 R 15c C is optionally replaced by one, two, three, or four elements selected from the above. 1-9 It is a heteroaryl, Z 1 CR 1b or N, R 1 C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, and each is R 15a It is optionally replaced by one, two, or three elements selected from the following: R 1b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: X is -C(R 6 )(R 6a )-, -S-, -O-, or -N(R 7)- and, R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Alternatively, R 6 and R 6a They come together to form an oxo, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Ring A is C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9It is a heteroaryl, Each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13-CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13-S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on adjacent carbon atoms 15e They combine to form a C2 alkenylene, Alternatively, two R atoms on the same atom 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13-S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 They form heteroaryls, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10)(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, n is between 0 and 6. R 10 These are hydrogen and C, respectively. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 These are hydrogen and C, respectively. 1-6 Alkyl, or C 1-6 It is a haloalkyl, R 12 These are hydrogen and C, respectively. 1-6 Alkyl, or C 1-6 It is a haloalkyl, and also R 13 These are hydrogen and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryl groups.

[0358] In some embodiments of the compound of formula (V), R 2 R 15c It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, three, or four groups selected from the above.

[0359] In some embodiments of the compound of formula (V), R 2 R 15c It is a six-membered heteroaryl molecule that is optionally substituted with one, two, three, or four groups selected from the above.

[0360] In some embodiments of the compound of formula (V), R 2 R 15c It is a pyridinyl molecule that is optionally substituted with one, two, three, or four groups selected from the following.

[0361] In some embodiments of the compound of formula (V), R 2 is

[0362]

Chemical formula

[0363] In some embodiments of the compound of formula (V), ring A is C 3-6 cycloalkyl or C 2-9 heterocycloalkyl.

[0364] In some embodiments of the compound of formula (V), ring A is C 2-9 heterocycloalkyl.

[0365] In some embodiments of the compound of formula (V), ring A is C 2-6 heterocycloalkyl.

[0366] In some embodiments of the compound of formula (V), ring A is C 6-9 heterocycloalkyl. In some embodiments of the compound of formula (V), ring A is a 6-membered heterocycloalkyl. In some embodiments of the compound of formula (V), ring A is a 5- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from O and N. In some embodiments of the compound of formula (V), ring A is a 6-membered heterocycloalkyl containing one heteroatom which is O.

[0367] In some embodiments of the compound of formula (V), R 15e are each independently halogen, oxo, -CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, -CH2-C 3-6 cycloalkyl, C 2-9 heterocycloalkyl, -CH2-C 2-9 heterocycloalkyl, C 6-10 aryl, -CH2-C 6-10 aryl, C1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 )

[0368] In some embodiments of the compound of formula (V), R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0369] In some embodiments of the compound of formula (V), R 15e These are, independently, halogen, oxo, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0370] In some embodiments of the compound of formula (V), two R on adjacent carbons 15e These combine to form a C2 alkenylene.

[0371] In some embodiments of the compound of formula (V), two R atoms on the same atom 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0372] In some embodiments of the compound of formula (V), two R atoms on the same atom 15eThese are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0373] In some embodiments of the compound of formula (V), two R atoms on the same atom 15e They become one, C 3-6 It forms a cycloalkyl group.

[0374] In some embodiments of the compound of formula (V), two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0375] In some embodiments of the compound of formula (V), two R atoms on different atoms 15e These are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0376] In some embodiments of the compound of formula (V), two R atoms on different atoms 15e They become one, C 3-6 It forms a cycloalkyl group.

[0377] In some embodiments of the compound of formula (V), n is 0 to 4. In some embodiments of the compound of formula (V), n is 2 to 4. In some embodiments of the compound of formula (V), n is 2. In some embodiments of the compound of formula (V), n is 1 or 2. In some embodiments of the compound of formula (V), n is 1. In some embodiments of the compound of formula (V), n is 1 to 3.

[0378] In some embodiments of the compound of formula (V),

[0379] [ka] teeth,

[0380] [ka] That is the case.

[0381] In some embodiments of the compound of formula (V), Z 1 is N. In some embodiments of the compound of formula (V), Z 1 CR 1b That is the case.

[0382] In some embodiments of the compound of formula (V), R 1b R is hydrogen or halogen. In some embodiments of the compound of formula (V), 1b It is hydrogen.

[0383] In some embodiments of the compound of formula (V), X is -C(R 6 )(R 6a)-, -S-, or -O-. In some embodiments of the compound of formula (V), X is -C(R 6 )(R 6a )- or -O-. In some embodiments of the compound of formula (V), X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (V), X is -O-. In some embodiments of the compound of formula (V), X is -S-. In some embodiments of the compound of formula (V), X is -N(R 7 )-. In some embodiments of the compound of formula (V), X is -S-, -O-, or -N(R 7 )-is.

[0384] In some embodiments of the compound of formula (V), R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, or C 1-6 It is a haloalkyl compound. In some embodiments of the compound of formula (V), R 6 and R 6a These are independently hydrogen or C 1-6 It is alkyl. In some embodiments of the compound of formula (V), R 6 and R 6a is hydrogen. In some embodiments of the compound of formula (V), R 6 and R 6a These combine to form an oxo.

[0385] In some embodiments of the compound of formula (V), R 7 is hydrogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl compound. In some embodiments of the compound of formula (V), R 7 is hydrogen or C 1-6 It is alkyl. In some embodiments of the compound of formula (V), R 7 It is hydrogen.

[0386] In some embodiments of the compound of formula (V), R1 is C 6-10 Aryl or C 1-9 It is a heteroaryl, and each is R 15a It is optionally replaced by one, two, or three elements selected from the set.

[0387] In some embodiments of the compound of formula (V), R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl compound.

[0388] In some embodiments of the compound of formula (V), R 1 R 15a It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0389] In some embodiments of the compound of formula (V), R 1 R 15a It is a five-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0390] In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9 It is a heteroaryl compound. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1is a monocyclic heteroaryl. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0391] In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (IV), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15aIt is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (V), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from.

[0392] In some embodiments of the compound of formula (V), R 1 C is selected from pyrazolyl and thiazolyl. 1-9 It is a heteroaryl compound, and pyrazolyl and thiazolyl are R 15a It is optionally replaced by one, two, or three elements selected from the set.

[0393] In some embodiments of the compound of formula (V), R 1 R 15aThiazolyl is optionally substituted with one, two, or three groups selected from the following.

[0394] In some embodiments of the compound of formula (V), R 1 R 15a It is a pyrazolyl compound that is optionally substituted with one, two, or three groups selected from the following.

[0395] In some embodiments of the compound of formula (V), R 1 teeth

[0396] [ka] In some embodiments of the compound of formula (V), R 1 teeth

[0397] [ka] That is the case.

[0398] In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11) is. In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0399] In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c They are independent of halogen and C1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (V), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0400] In some embodiments of the compound of formula (V), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11) is. In some embodiments of the compound of formula (V), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15a Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15a Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15a Each is independent of C 1-6 Alkyl or -OR 10In some embodiments of the compound of formula (V), R 15a Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (V), R 15a Each is independent of the other, -OR 10 That is the case.

[0401] In some embodiments of the compound of formula (V), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0402] In some embodiments of the compound of formula (V), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15b Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15b Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15b Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (V), R 15b Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (V), R 15b Each is independent of the other, -OR 10 That is the case.

[0403] In some embodiments of the compound of formula (V), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (V), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0404] In some embodiments of the compound of formula (V), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15c Each of them is independent of halogen and C 1-6Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15c Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15c Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (V), R 15c Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (V), R 15c Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (V), R 15c Each is independent of the other, -OR 10 That is the case.

[0405] In some embodiments, formula (VI)

[0406] [ka] Compounds thereof, or pharmaceutically acceptable salts or solvates thereof, are disclosed herein. During the ceremony, R 2 C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, and each is R 15c It is optionally replaced by one, two, three, or four elements selected from the following: Z 1 CR 1b or N, R 1 C 3-6 Cycloalkyl, C 2-9Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, and each is R 15a It is optionally replaced by one, two, or three elements selected from the following: R 1b Hydrogen, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 -SF5, -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls are R 15b It is optionally replaced by one, two, or three elements selected from the following: X is -C(R 6 )(R 6a )-, -S-, -O-, or -N(R 7 )- and, R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Ariel, C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Alternatively, R 6 and R 6a They come together to form an oxo, R 7 is hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Selected from heteroaryls, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, Ring B is C 3-6 Cycloalkyl, C 6-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, Each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)OR13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , or -CH2S(O)2N(R 10 )(R 11 ) and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, -CH2-C 3-10 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, -CH2-C 1-9 Heteroaryls, and C 1-9 Heteroaryls include halogens, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on adjacent carbon atoms 15e They combine to form a C2 alkenylene, Alternatively, two R atoms on the same atom 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R10 )(R 11 ), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, Alternatively, two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 They form heteroaryls, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , -SR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 ,-OC(O)N(R 10 )(R 11 ), -N(R 12 )C(O)N(R 10 )(R 11), -N(R 12 )C(O)OR 13 , -N(R 12 )S(O)2R 13 , -C(O)R 13 ,-S(O)R 13 ,-OC(O)R 13 ,-C(O)N(R 10 )(R 11 ), -C(O)C(O)N(R 10 )(R 11 ), -N(R 12 )C(O)R 13 -S(O)2R 13 -S(O)2N(R 10 )(R 11 )-, S(O)(NH)N(R 10 )(R 11 ), -CH2C(O)N(R 10 )(R 11 ), -CH2N(R 12 )C(O)R 13 -CH2S(O)2R 13 , and -CH2S(O)2N(R 10 )(R 11 ) is optionally replaced by one, two, or three elements independently selected from the above, n is between 0 and 6. R 10 These are hydrogen and C, respectively. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Optionally substituted with one, two, or three groups selected from heteroaryls, R 11 These are hydrogen and C, respectively. 1-6 Alkyl, or C 1-6 It is a haloalkyl, R 12 These are hydrogen and C, respectively. 1-6 Alkyl, or C 1-6 It is a haloalkyl, and also R 13 These are hydrogen and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryl groups.

[0407] In some embodiments of the compound of formula (VI), R 2 is C 6-10 Aryl or C 1-9 It is a heteroaryl, and each is R 15cIt is optionally replaced by one, two, three, or four elements selected from the set.

[0408] In some embodiments of the compound of formula (VI), R 2 R 15c C is optionally replaced by one, two, three, or four elements selected from the above. 1-9 It is a heteroaryl compound.

[0409] In some embodiments of the compound of formula (VI), R 2 R 15c It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, three, or four groups selected from the above.

[0410] In some embodiments of the compound of formula (VI), R 2 R 15c It is a six-membered heteroaryl molecule that is optionally substituted with one, two, three, or four groups selected from the above.

[0411] In some embodiments of the compound of formula (VI), R 2 R 15c It is a pyridinyl molecule that is optionally substituted with one, two, three, or four groups selected from the following.

[0412] In some embodiments of the compound of formula (VI), R 2 R 15c It is a phenyl molecule that is optionally substituted with one, two, three, or four groups selected from the following.

[0413] In some embodiments of the compound of formula (VI), R 2 teeth

[0414] [ka] That is the case.

[0415] In some embodiments of the compound of formula (VI), ring B is C 6-9It is heterocycloalkyl.

[0416] In some embodiments of the compound of formula (VI), R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 )

[0417] In some embodiments of the compound of formula (VI), R 15e These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0418] In some embodiments of the compound of formula (VI), R 15e These are, independently, halogen, oxo, and C. 1-6 Alkyl, or C 1-6 It is a haloalkyl group.

[0419] In some embodiments of the compound of formula (VI), two R on adjacent carbons 15e These combine to form a C2 alkenylene.

[0420] In some embodiments of the compound of formula (VI), two R atoms on the same atom 15e They become one, C 3-6Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0421] In some embodiments of the compound of formula (VI), two R atoms on the same atom 15e These are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0422] In some embodiments of the compound of formula (VI), two R atoms on the same atom 15e They become one, C 3-6 It forms a cycloalkyl group.

[0423] In some embodiments of the compound of formula (VI), two R atoms on different atoms 15e They become one, C 3-6 Cycloalkyl or C 2-9 They form heterocycloalkyl groups, each consisting of a halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 It is optionally replaced by one, two, or three elements selected independently of ).

[0424] In some embodiments of the compound of formula (VI), two R atoms on different atoms 15e These are, together, halogen, oxo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 10 , and -N(R 10 )(R 11 C is optionally replaced by one, two, or three elements independently selected from ). 3-6 It forms a cycloalkyl group.

[0425] In some embodiments of the compound of formula (VI), two R atoms on different atoms 15e They become one, C 3-6 It forms a cycloalkyl group.

[0426] In some embodiments of the compound of formula (VI), n is 0 to 4. In some embodiments of the compound of formula (VI), n is 2 to 4. In some embodiments of the compound of formula (VI), n is 2. In some embodiments of the compound of formula (VI), n is 1 or 2. In some embodiments of the compound of formula (VI), n is 1. In some embodiments of the compound of formula (VI), n is 1 to 3.

[0427] In some embodiments of the compound of formula (VI),

[0428] [ka] teeth,

[0429] [ka] That is the case.

[0430] In some embodiments of the compound of formula (VI), Z 1is N. In some embodiments of the compound of formula (VI), Z 1 CR 1b That is the case.

[0431] In some embodiments of the compound of formula (VI), R 1b is hydrogen or halogen. In some embodiments of the compound of formula (VI), R 1b It is hydrogen.

[0432] In some embodiments of the compound of formula (VI), X is -C(R 6 )(R 6a )-, -S-, or -O-. In some embodiments of the compound of formula (VI), X is -C(R 6 )(R 6a )- or -O-. In some embodiments of the compound of formula (VI), X is -C(R 6 )(R 6a )-. In some embodiments of the compound of formula (VI), X is -O-. In some embodiments of the compound of formula (VI), X is -S-. In some embodiments of the compound of formula (VI), X is -N(R 7 )-. In some embodiments of the compounds of formula (VI), X is -S-, -O-, or -N(R 7 )-is.

[0433] In some embodiments of the compound of formula (VI), R 6 and R 6a They are independently hydrogen, halogen, and C 1-6 Alkyl, or C 1-6 It is a haloalkyl compound. In some embodiments of the compound of formula (VI), R 6 and R 6a These are independently hydrogen or C 1-6 It is alkyl. In some embodiments of the compound of formula (VI), R 6 and R 6a is hydrogen. In some embodiments of the compound of formula (VI), R 6 and R 6aThese combine to form an oxo.

[0434] In some embodiments of the compound of formula (VI), R 7 is hydrogen, C 1-6 Alkyl, or C 1-6 It is a haloalkyl compound. In some embodiments of the compound of formula (VI), R 7 is hydrogen or C 1-6 It is alkyl. In some embodiments of the compound of formula (VI), R 7 It is hydrogen.

[0435] In some embodiments of the compound of formula (VI), R 1 is C 6-10 Aryl or C 1-9 It is a heteroaryl, and each is R 15a It is optionally replaced by one, two, or three elements selected from the set.

[0436] In some embodiments of the compound of formula (VI), R 1 R 15a C is optionally replaced by one, two, or three elements selected from the above. 1-9 It is a heteroaryl compound.

[0437] In some embodiments of the compound of formula (VI), R 1 R 15a It is a 5- or 6-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0438] In some embodiments of the compound of formula (VI), R 1 R 15a It is a five-membered heteroaryl that is optionally substituted with one, two, or three groups selected from the above.

[0439] In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 C is replaced by an optional substitution. 1-9It is a heteroaryl compound. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted 5 or 6-membered heteroaryl. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted five-membered heteroaryl. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 R is an optionally substituted six-membered heteroaryl. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 is a monocyclic heteroaryl. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 It is a bicyclic heteroaryl. In some embodiments, R 1 is R 15a It is optionally replaced with one, two, or three bases selected from. In some embodiments, R 1 is halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 It is optionally substituted with one, two, or three groups selected from alkoxyls. In some embodiments, R 1 These are oxo, -CN, amino, OH, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxyl, and C 3-6 It is optionally substituted with one, two, or three groups selected from cycloalkyl groups.

[0440] In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is optionally substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a It is selectively substituted with one, two, or three groups selected from. In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one, two, or three groups selected from R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl and -OR 10 Selected from: In some embodiments of the compound of formula (VI), or its pharmaceutically acceptable salt or solvate, R 1 C is selected from pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl. 1-9 These are heteroaryl compounds, and pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, pyridadinyl, and pyridinyl are R 15a Substituted with one group selected from R 15a is halogen, C 1-6 Alkyl, C1-6 Haloalkyl and -OR 10 Selected from.

[0441] In some embodiments of the compound of formula (VI), R 1 C is selected from pyrazolyl and thiazolyl. 1-9 It is a heteroaryl compound, and pyrazolyl and thiazolyl are R 15a It is optionally replaced by one, two, or three elements selected from the set.

[0442] In some embodiments of the compound of formula (VI), R 1 R 15a Thiazolyl is optionally substituted with one, two, or three groups selected from the following.

[0443] In some embodiments of the compound of formula (VI), R 1 R 15a It is a pyrazolyl compound that is optionally substituted with one, two, or three groups selected from the following.

[0444] In some embodiments of the compound of formula (VI), R 1 teeth

[0445] [ka] In some embodiments of the compound of formula (VI), R 1 teeth

[0446] [ka] That is the case.

[0447] In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c These are independently halogen, oxo, -CN, and C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0448] In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R15c They are independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c They are independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (VI), each R 15a , each R 15b , and each R 15c These are independent, -OR 10 That is the case.

[0449] In some embodiments of the compound of formula (VI), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15a These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each of them is independent of halogen and C 1-6 Alkyl, C3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15a Each is independent of the other, -OR 10 That is the case.

[0450] In some embodiments of the compound of formula (VI), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15b These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0451] In some embodiments of the compound of formula (VI), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each is independent of C 1-6Alkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15b Each is independent of the other, -OR 10 That is the case.

[0452] In some embodiments of the compound of formula (VI), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -CH2-C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, -CH2-C 2-9 Heterocycloalkyl, C 6-10 Ariel, -CH2-C 6-10 Ariel, C 1-9 Heteroaryl, -CH2-C 1-9 Heteroaryl, -OR 10 , -N(R 10 )(R 11 ), -C(O)OR 10 , -C(O)R 13 , or -C(O)N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, -OR 10 , or -N(R 10 )(R 11 ) is. In some embodiments of the compound of formula (VI), R 15c These are, independently, halogen, oxo, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, -OR 10 , or -N(R 10 )(R 11) is. In some embodiments of the compound of formula (VI), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, or -OR 10 That is the case.

[0453] In some embodiments of the compound of formula (VI), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 1-6 Haloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each of them is independent of halogen and C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each of them is independent of halogen and C 1-6 Alkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each is independent of C 1-6 Alkyl, C 3-10 Cycloalkyl, or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each is independent of C 1-6 Alkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each is independent of C 3-10 Cycloalkyl or -OR 10 In some embodiments of the compound of formula (VI), R 15c Each is independent of the other, -OR 10 That is the case.

[0454] In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 2-9 It is a heterocycloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, and C 2-9 Heterocycloalkyls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, or C 1-6 It is a haloalkyl, C 1-6 Alkyl is a halogen, -CN, hydroxy, C 1-6Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each of them is independently of hydrogen and C 1-6 Alkyl, or C 1-6 It is a haloalkyl. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each is independent of C 1-6 Alkyl or C 1-6 It is a haloalkyl. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each is independent of C 1-6 It is alkyl. In some embodiments of the compounds of formula (IV), (V), or (VI), each R 10 is methyl. In some embodiments of the compounds of formula (IV), (V), or (VI), R 10 Each is independent of C 1-6 It is a haloalkyl group.

[0455] In some embodiments of the compounds of formula (IV), (V), or (VI), R 11 Each of them independently represents hydrogen or C 1-6 It is alkyl. In some embodiments of compounds of formula (IV), (V), or (VI), R 11 Each is independently hydrogen. In some embodiments of the compounds of formula (IV), (V), or (VI), R 11 Each is independent of C 1-6 It is alkyl. In some embodiments of compounds of formula (IV), (V), or (VI), R 12 Each of them is independently of hydrogen and C 1-6 Alkyl, or C 1-6It is a haloalkyl. In some embodiments of the compounds of formula (IV), (V), or (VI), R 12 Each of them independently represents hydrogen or C 1-6 It is alkyl. In some embodiments of compounds of formula (IV), (V), or (VI), R 12 Each is independently hydrogen. In some embodiments of the compounds of formula (IV), (V), or (VI), R 12 Each is independent of C 1-6 It is alkyl.

[0456] In some embodiments of the compounds of formula (IV), (V), or (VI), R 13 Each of them is independently of hydrogen and C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C 1-9 It is a heteroaryl, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 13 Each of them is independently of hydrogen and C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, or C1-9 It is a heteroaryl, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 Heteroaryls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 13 Each of them is independently of hydrogen and C 1-6 Alkyl, C 3-6 Cycloalkyl, or C 2-9 It is a heterocycloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, and C 2-9 Heterocycloalkyls include halogen, -CN, hydroxy, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 It is optionally substituted with one, two, or three groups selected from heteroaryls. In some embodiments of the compounds of formula (IV), (V), or (VI), R 13 These are independently hydrogen, halogen, -CN, hydroxyl, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-9 Heterocycloalkyl, C 6-10 Aryl, and C 1-9 C is optionally substituted with one, two, or three groups selected from heteroaryl groups.1-6 It is alkyl. In some embodiments of compounds of formula (IV), (V), or (VI), R 13 Each of them independently represents hydrogen or C 1-6 It is alkyl. In some embodiments of compounds of formula (IV), (V), or (VI), R 13 Each is independent of C 1-6 It is alkyl.

[0457] Any combination of the above groups is contemplated herein for various variables. Throughout the specification, the groups and their substituents are selected by those skilled in the art to provide stable moieties and compounds.

[0458] In some embodiments, compounds, or pharmaceutically acceptable salts or solvates thereof, are provided herein, and the compounds are selected from the compounds in Table 1B.

[0459] [Table 2-1]

[0460] [Table 2-2]

[0461] In some embodiments, compounds, or pharmaceutically acceptable salts or solvates thereof, are provided herein, and the compounds are selected from the compounds in Table 1C.

[0462] [Table 3]

[0463] Further forms of the compounds disclosed herein Isomers / stereoisomers In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers and their corresponding mixtures. In some cases, the compounds described herein have one or more chiral centers, each center existing in either an R or S configuration. The compounds described herein include all diastereomers, enantiomers, and epimers, as well as their corresponding mixtures. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers derived from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as individual stereoisomers of the compound by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. In some embodiments, separable complexes are preferred. In some embodiments, the diastereomers have characteristic physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.) and are separated by utilizing these differences. In some embodiments, the diastereomers are separated by chiral chromatography or, preferably, by separation / resolving techniques based on differences in solubility. In some embodiments, the optically pure enantiomer is recovered together with the resolving agent by any practical means that does not result in racemization.

[0464] labeled compound In some embodiments, the compounds described herein exist in isotope-labeled forms. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such isotope-labeled compounds. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such isotope-labeled compounds, such as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotope-labeled compounds that are identical to those enumerated herein, apart from the fact that one or more atoms are replaced by atoms having atomic masses or mass numbers different from those normally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein are isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, for example, 2 H(D), 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Contains Cl. Compounds described herein, and their pharmaceutically acceptable salts, solvates, or stereoisomers, containing the aforementioned isotopes and / or other isotopes of other atoms, are within the scope of this disclosure. Certain isotope-labeled compounds, for example, 3 H 14 Isotope-labeled compounds, which incorporate radioactive isotopes such as 13C, are useful in drug and / or substrate tissue distribution assays. Tritium-labeled compounds, i.e., 3 H, and carbon-14, that is, 14 13C isotopes are particularly preferred because they are easy to prepare and detect. In some embodiments, the compounds described herein can be artificially enriched in one or more isotopes that are not naturally dominant. In some embodiments, the compounds described herein are enriched in deuterium ( 2 H), tritium ( 3H), Iodine-125( 125 I) or carbon-14 ( 14 They can be artificially enriched in one or more isotopes selected from C). In some embodiments, the compounds described herein are 2 H, 11 C, 13 C, 14 C, 15 C, 12 N, 13 N, 15 N, 16 N, 16 O, 17 O, 14 F, 15 F, 16 F, 17 F, 18 F, 33 S, 34 S, 35 S, 36 S, 35 Cl, 37 Cl, 79 Br, 81 Br, 131 I, and 125 The isotopes are artificially enriched in one or more isotopes selected from I. In some embodiments, the abundance of the enriched isotopes is independently at least 1 mol%, at least 10 mol%, at least 20 mol%, at least 30 mol%, at least 40 mol%, at least 50 mol%, at least 60 mol%, at least 70 mol%, at least 80 mol%, at least 90 mol%, or at least 100 mol%.

[0465] In some embodiments, the amount of deuterium present in each of the substituents disclosed herein is independently at least 1 mol%, at least 10 mol%, at least 20 mol%, at least 30 mol%, at least 40 mol%, at least 50 mol%, at least 60 mol%, at least 70 mol%, at least 80 mol%, at least 90 mol%, or at least 100 mol%. In some embodiments, one or more substituents disclosed herein contain a higher proportion of deuterium than the natural abundance of deuterium. In some embodiments, one or more 1H is substituted with one or more deuterium atoms in one or more of the substituents disclosed herein.

[0466] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0467] Pharmaceutically acceptable salts In some embodiments, the compounds described herein exist as pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.

[0468] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with many inorganic or organic bases, as well as either inorganic or organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or their solvates or stereoisomers, or by separately reacting the purified compounds in their free form with a suitable acid or base and isolating the salts thus formed.

[0469] Examples of pharmaceutically acceptable salts include salts prepared by the reaction of minerals, organic acids, or inorganic bases with the compounds described herein, such as acetates, acrylates, adipicates, alginates, aspartates, benzoates, benzenesulfons, bisulfates, bisulfites, bromides, butyrates, butynate-1,4-dioate, camphorates, camphor sulfons, caproates, caprylates, chlorobenzoic acid, chlorides, citrates, cyclopentanepropionates, decanoates, and diglucons. Dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyn-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate Examples include metaphosphates, methanesulfonates, methoxybenzoates, methylbenzoates, monohydrogen phosphates, 1-naphthalenesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, palmoate, pectinates, persulfates, phenyl 3-propionate, phosphates, picrates, pivalates, propions, pyrosulfates, pyrophosphates, propiolates, phthalates, phenylacetates, phenylbutyrates, propanesulfonates, salicylates, succinates, sulfates, sulfites, succinates, suberinates, sebacinates, sulfonates, tartrates, thiocyanates, undecone tosylate, and xylenesulfonates.

[0470] Furthermore, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compounds with a pharmaceutically acceptable inorganic or organic acid, and the inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the organic acids include, but are not limited to, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoic acid) This includes benzoic acid, cinnamic acid, mandelic acid, aryl sulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]octa-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. In some embodiments, other acids that are not pharmaceutically acceptable on their own, such as oxalic acid, are used in the preparation of salts that are useful as intermediates in obtaining the compounds disclosed herein, their solvates or stereoisomers, and their pharmaceutically acceptable acid addition salts.

[0471] In some embodiments, these compounds described herein, which contain free acid groups, react with a suitable base of a pharmaceutically acceptable metal cation, such as hydroxides, carbonates, bicarbonates, or sulfates, and with ammonia or a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Typical salts include alkali or alkaline earth salts such as lithium, sodium, potassium, calcium, and magnesium, as well as aluminum salts. Exemplary examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and N2. + (C 1-4It contains alkyl(4) and other elements.

[0472] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, and piperazine. Note that the compounds described herein also include quaternization of any basic nitrogen-containing group they contain. In some embodiments, water-soluble, oil-soluble, or dispersible products are obtained by such quaternization.

[0473] solvate In some embodiments, the compounds described herein exist as solvates. This disclosure provides a meth...

Claims

1. A method for treating cancer in a subject requiring treatment, wherein the method applies to the subject, (a) Equation (I) 【Chemistry 1】 The compound of, or a pharmaceutically acceptable salt thereof. (In the formula, Y １ CR １ａ or N, Y ２ CR ２ａ or N, Y ３ CR ３ａ or N, Y ４ CR ４ａ or N, Y ５ is CR ５ａ or N, and Z １ CR １ｂ or N, Z ２ CR ２ｂ or N, Z ３ CR ３ｂ Or N, Y １ , Y ２ , Y ３ , Y ４ , Y ５ Z １ Z ２ , and Z ３ At least one of them is N, X is -C(R ６ ) (Caution ６ａ )-, -O-, and -N(R ７ ) - Selected from, R １ R １５ａ C is optionally replaced by one, two, or three elements selected from the above. １－９ It is a heteroaryl, R １ａ , R ２ａ , R ３ａ , R ４ａ , R ５ａ , R １ｂ , R ２ｂ , and R ３ｂ These are independently hydrogen, halogen, and C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Ariel, C １－９ heteroaryl, -OR １０ , -SR １０ , -SF ５ , -N(R １０ ) (Caution １１ ), -C(O)OR １０ , -OC(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)OR １３ , -N(R １２ ) S(O) ２ R １３ , -C(O)R １３ , -S(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (Caution １１ ), -C(O)C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)R １３ , -S(O) ２ R １３ , -S(O) ２ N(R) １０ ) (Caution １１ )-, S(=O)(=NH)N(R １０ ) (Caution １１ ), -CH ２ C(O)N(R) １０ ) (Caution １１ ), -CH ２ N(R) １２ ) C(O)R １３ , -CH ２ S(O) ２ R １３ , and -CH ２ S(O) ２ N(R １０ )(R １１ ) is selected from, C １－６ alkyl, C ２－６ alkenyl, C ２－６ alkynyl, C ３－６ cycloalkyl, C ２－９ heterocycloalkyl, C ６－１０ aryl, and C １－９ heteroaryl is optionally substituted with one, two, or three groups selected from R １５ｂ ​ R ６ and R ６ａ These are independently hydrogen, halogen, and C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Ariel, C １－９ heteroaryl, -OR １０ , -SR １０ , -N(R １０ ) (Caution １１ ), -C(O)OR １０ , -OC(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)OR １３ , -N(R １２ ) S(O) ２ R １３ , -C(O)R １３ , -S(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (Caution １１ ), -C(O)C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)R １３ , -S(O) ２ R １３ , -S(O) ２ N(R) １０ ) (Caution １１ )-, S(=O)(=NH)N(R １０ ) (Caution １１ ), -CH ２ C(O)N(R) １０ ) (Caution １１ ), -CH ２ N(R) １２ ) C(O)R １３ ien-CH ２ S(O) ２ R １３ , and -CH ２ S(O) ２ N(R) １０ ) (Caution １１ ) is selected from C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryls are halogens, -CN, hydroxy, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Optionally substituted with one, two, or three groups selected from heteroaryls, R ７ is hydrogen, C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Selected from heteroaryls, C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryls are halogens, -CN, hydroxy, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Optionally substituted with one, two, or three groups selected from heteroaryls, R １０ Each of them is independently of hydrogen and C １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Selected from heteroaryls, C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryls are halogens, -CN, hydroxy, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Optionally substituted with one, two, or three groups selected from heteroaryls, R １１ Each of them is independently of hydrogen and C １－６ Alkyl and C １－６ Selected from haloalkyl groups, R １２ Each of them is independently of hydrogen and C １－６ Alkyl and C １－６ Selected from haloalkyl groups, R １３ Each is independent of C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Selected from heteroaryls, C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Heteroaryls are halogens, -CN, hydroxy, C １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, C ６－１０ Aryl, and C １－９ Optionally substituted with one, two, or three groups selected from heteroaryls, Each R １５ａ and each R １５ｂ These are, independently, halogen, oxo, -CN, and C. １－６ Alkyl, C １－６ Haloalkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－１０ Cycloalkyl, -CH ２ -C ３－６ Cycloalkyl, C ２－９ Heterocycloalkyl, -CH ２ -C ２－９ Heterocycloalkyl, C ６－１０ Ariel, -CH ２ -C ６－１０ Ariel, C １－９ Heteroaryl, -CH ２ -C １－９ heteroaryl, -OR １０ , -SR １０ , -N(R １０ ) (Caution １１ ), -C(O)OR １０ , -OC(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)OR １３ , -N(R １２ ) S(O) ２ R １３ , -C(O)R １３ , -S(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (Caution １１ ), -C(O)C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)R １３ , -S(O) ２ R １３ , -S(O) ２ N(R) １０ ) (Caution １１ )-, S(=O)(=NH)N(R １０ ) (Caution １１ ), -CH ２ C(O)N(R) １０ ) (Caution １１ ), -CH ２ N(R) １２ ) C(O)R １３ ien-CH ２ S(O) ２ R １３ , and -CH ２ S(O) ２ N(R) １０ ) (Caution １１ ) is selected from C １－６ Alkyl, C ２－６ Alkenil, C ２－６ Alkinyl, C ３－６ Cycloalkyl, -CH ２ -C ３－１０ Cycloalkyl, C ２－９ Heterocycloalkyl, -CH ２ -C ２－９ Heterocycloalkyl, C ６－１０ Ariel, -CH ２ -C ６－１０ Ariel, -CH ２ -C １－９ Heteroaryls, and C １－９ Heteroaryls include halogens, oxo, -CN, and C. １－６ Alkyl, C １－６ Haloalkyl, C １－６ Alkoxy, C １－６ Haloalkoxy, -OR １０ , -SR １０ , -N(R １０ ) (Caution １１ ), -C(O)OR １０ , -OC(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)OR １３ , -N(R １２ ) S(O) ２ R １３ , -C(O)R １３ , -S(O)R １３ , -OC(O)R １３ , -C(O)N(R １０ ) (Caution １１ ), -C(O)C(O)N(R １０ ) (Caution １１ ), -N(R １２ ) C(O)R １３ , -S(O) ２ R １３ , -S(O) ２ N(R) １０ ) (Caution １１ )-, S(=O)(=NH)N(R １０ ) (Caution １１ ), -CH ２ C(O)N(R) １０ ) (Caution １１ ), -CH ２ N(R) １２ ) C(O)R １３ ien-CH ２ S(O) ２ R １３ , and -CH ２ S(O) ２ N(R) １０ ) (Caution １１ (which is optionally replaced by one, two, or three elements selected independently of the original element.) (b) Additional anticancer drugs The process includes administering A method wherein the total amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof and additional agents is therapeutically effective in treating cancer.

2. A method for treating cancer in a subject requiring treatment, wherein the method applies to the subject, (a) 2,4-dimethoxy-N-(4-methoxy-6-(thiazole-2-yloxy)benzo[d]isoxazole-3-yl)-6-methylpyridine-3-sulfonamide 【Chemistry 2】 or a pharmaceutically acceptable salt thereof, (b) Additional drugs that are anticancer drugs, A method comprising the step of administering a substance.

3. The method according to claim 2, wherein the total amount of compound 57 or a pharmaceutically acceptable salt thereof and the additional agent is therapeutically effective.

4. The method according to any one of claims 1 to 3, wherein the cancer is selected from lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, melanoma of the skin or eye, multiple myeloma, uterine cancer, ovarian cancer, rectal cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer (CRC), breast cancer, endometrial cancer, cervical cancer, vaginal cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, hematological malignancies, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureteral cancer, renal cell carcinoma, renal pelvis cancer, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axial tumor, glioblastoma, brainstem glioma, pituitary adenoma, or two or more combinations of the aforementioned cancers.

5. The method according to any one of claims 1 to 4, wherein the cancer is breast cancer.

6. The method according to claim 5, wherein the breast cancer is HR+ / HER2- breast cancer.

7. The method according to claim 6, wherein the HR+ / HER2- breast cancer is ER+ / HER2- breast cancer.

8. The aforementioned ER+ / HER2- breast cancer is classified as ER+ / KAT6a. ｈｉｇｈ The method according to claim 7, wherein the patient has breast cancer.

9. The aforementioned HR+ / HER2- breast cancer, ER+ / HER2- breast cancer, or ER+ / KAT6a ｈｉｇｈ The method according to any one of claims 6 to 8, wherein the breast cancer is resistant to endocrine therapy or chemotherapy.

10. The method according to claim 9, wherein the breast cancer is resistant to endocrine therapy, and the subject is optionally treated with endocrine therapy.

11. The method according to claim 10, wherein the endocrine therapy comprises SERM, SERD, an aromatase inhibitor, or a CDK inhibitor.

12. The method according to any one of claims 5 to 11, wherein the breast cancer is characterized by a TP53 mutation, an ESR1 mutation, loss of Rb function, and / or CCNE amplification.

13. The method according to claim 12, wherein the ESR1 mutation includes L536Q, Y537N, Y537S, D538G, and / or E380Q.

14. The method according to claim 9, wherein the breast cancer is resistant to chemotherapy, and the subject is optionally treated with chemotherapy.

15. The method according to claim 14, wherein the chemotherapy is epirubicin, doxorubicin, cyclophosphamide, docetaxel, paclitaxel, carboplatin, gemcitabine, lobaplatin, nab-paclitaxel, cisplatin, or capecitabine.

16. The method according to claim 11, wherein the CDK inhibitor includes a CDK2 selective inhibitor, a CDK4 selective inhibitor, a CDK2 / 4 / 6 selective inhibitor, or a CDK4 / 6 selective inhibitor.

17. The method according to claim 11, wherein the CDK inhibitor includes a CDK4 / 6 selective inhibitor.

18. The method according to claim 16 or 17, wherein the CDK inhibitor is PF-07220060, arbocidicib, AT7519, JNJ-7706621, PHA-793887, BMS-265246, milciclib (PHA-848125), R547, ribiclib (P276-00), MC180295, G1T38, ON123300, pluvaranol A, SU9516, ribociclib (LEE011), or BSJ-03-123, palbociclib, abemaciclib, or dalpicilib, or a pharmaceutically acceptable salt thereof.

19. The aforementioned cancers include NSCLC, small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and ER+ / KAT6a. ｈｉｇｈ The method according to any one of claims 1 to 4, wherein the cancer is breast cancer, melanoma, colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, or ovarian cancer.

20. The method according to claim 17, wherein the cancer is a NSCLC with an EGFR gene abnormality, and the NSCLC is optionally resistant to treatment with an EGFR inhibitor comprising afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, almonertinib, and / or flumonertinib.

21. The method according to claim 20, wherein the EGFR gene abnormality is an exon 19 deletion (19del) or a missense mutation comprising L858R, T790M, and / or C797S.

22. The method according to any one of claims 1 to 4, wherein the cancer is optionally multiple myeloma with 1q21 amplification.

23. The method according to any one of claims 1 to 4, wherein the cancer is acute myeloid leukemia (AML).

24. The method according to any one of claims 1 to 4, wherein the cancer is metastatic castration-resistant prostate cancer (mCRPC) or prostate cancer.

25. The method according to claim 24, wherein the metastatic castration-resistant prostate cancer (mCRPC) or prostate cancer is resistant to hormone therapy.

26. The method according to claim 24, wherein the metastatic castration-resistant prostate cancer (mCRPC) or prostate cancer is resistant to ADTs, androgen synthesis inhibitors, such as abiraterone, ketoconazole, and aminoglutethimide, or androgen receptor blockers, such as first-generation drugs flutamide, bicalutamide, and nilutamide, and second-generation drugs enzalutamide, apalutamide, and darolutamide.

27. The method according to any one of claims 1 to 26, wherein the additional agents include endocrine therapy agents, CDK inhibitors, PI3K-AKT-mTOR pathway inhibitors, androgen synthesis inhibitors, androgen receptor blockers, radiopharmaceuticals, immunotherapy agents, chemotherapeutic agents, Bcl-2 inhibitors, Bcl-xL inhibitors, or any combination thereof.

28. The method according to any one of claims 1 to 26, wherein the additional drug includes an endocrine therapy drug.

29. The method according to claim 28, wherein the endocrine therapy agent comprises SERM, SERD, or an aromatase inhibitor.

30. The method according to claim 29, wherein the endocrine therapy agent comprises tamoxifen, raloxifene, fulvestrant, elastrant, camizestrant, amcenestrant, goserelin, imurunestrant, giredestrant, or ARV-471, anastrozole, letrozole, exemestane, or a pharmaceutically acceptable salt thereof.

31. The method according to claim 29, wherein the endocrine therapy agent comprises elastolant.

32. The method according to any one of claims 1 to 26, wherein the additional agent comprises a CDK inhibitor.

33. The method according to claim 32, wherein the CDK inhibitor includes a CDK2 selective inhibitor, a CDK4 selective inhibitor, a CDK2 / 4 / 6 selective inhibitor, or a CDK4 / 6 selective inhibitor.

34. The method according to claim 33, wherein the CDK inhibitor is PF-07220060, arbocidicib, AT7519, JNJ-7706621, PHA-793887, BMS-265246, milciclib (PHA-848125), R547, ribicilib (P276-00), MC180295, G1T38, ON123300, pluvaranol A, SU9516, ribociclib (LEE011), or BSJ-03-123, palbociclib, abemaciclib, or dalpicilib, or a pharmaceutically acceptable salt thereof.

35. The method according to any one of claims 1 to 24, wherein the additional agent comprises a PI3K-AKT-mTOR pathway inhibitor.

36. The PI3K-AKT-mTOR pathway inhibitors mentioned above include alpelisib, rapamycin or its derivatives, sirolimus, everolimus, AZD8055, temsirolimus (CCI-779), PI-103, KU-0063794, tolkinib (PP242), ridafololimus (defololimus, MK-8669), sapanicertib (MLN0128), and voxtalisib (XL765). Trin-1, Trin-2, Omiparisib (GSK2126458), OSI-027, PF-04691502, Apitricib (GDC-0980), GSK1059615, Gedatolicib (PKI-587), WYE-354, Vistusertib (AZD2014), WYE-125132 (WYE-132), PP121, WYE-687, WAY-600, ETP-46464, GDC-0349, XL388, GNE-477, bimirallisib (PQR309), SF2523, CZ415, paxalisib (GDC-0084), CC-115, onatasertive (CC223), zotarolimus The method according to claim 35, comprising (ABT-578), tacrolimus (FK506), BGT226 maleic acid (NVP-BGT226 maleic acid), palomid 529 (P529), LY3023414 (samotricib), biolimus-7, biolimus-9, azathioprine, campas 1H, or chrysophanic acid, or pharmaceutically acceptable salts thereof.

37. The method according to any one of claims 1 to 26, wherein the additional drug includes a hormone therapy drug.

38. The method according to claim 37, wherein the additional agent is an androgen synthesis inhibitor.

39. The method according to claim 38, wherein the androgen synthesis inhibitor is abiraterone, ketoconazole, aminoglutethimide, dutasteride, epristeride, alpha-estradiol, or a pharmaceutically acceptable salt thereof.

40. The method according to any one of claims 1 to 26, wherein the additional agent is an androgen receptor blocker.

41. The method according to claim 40, wherein the androgen receptor blocker is flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide, or darolutamide, or a pharmaceutically acceptable salt thereof.

42. The method according to any one of claims 1 to 26, wherein the additional drug is an immunotherapy drug.

43. The method according to claim 42, wherein the immunotherapy agent is a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, a CTLA-4 inhibitor, a LAG-3 inhibitor, a TIM-3 inhibitor, a V-domain Ig inhibitor (VISTA) inhibitor for T cell activation, or a pharmaceutically acceptable salt thereof.

44. The method according to claim 43, wherein the inhibitor is a small molecule, a peptide, a nucleotide, or an antibody.

45. The method according to claim 43, wherein the immunotherapy agent includes nivolumab, pembrolizumab, pizilizumab, AMP-224, PF-06801591, MEDI0680, PDR001, REGN2810, SHR-12-1, TSR-042, CA-170, atezolizumab, durvalumab, KN035 and BMS-936559, ipilimumab, tremelimumab, AGEN1884, AGEN2041, BMS-986016, GSK2831781, IMP321, LAG525, MGD013, or TSR-022, or any combination thereof.

46. The method according to any one of claims 1 to 26, wherein the additional agent includes a chemotherapeutic agent.

47. The method according to claim 46, wherein the chemotherapeutic agent comprises azacitidine, decitabine, idarubicin, daunorubicin, cytarabine, pemetrexed, cisplatin, carboplatin, paclitaxel, nab-paclitaxel, gemcitabine, etoposide, irinotecan, topotecan, lurubinectedin, epirubicin, doxorubicin, liposomal doxorubicin, melphalan, bendamustine, thalidomide, lenalidomide, pomalidomide, bortezomib, serinexol, cyclophosphamide, docetaxel, lobaplatin, temozoloid, capecitabine, dacarbazine, 5-FU, cabazitaxel, mitoxantrone, or estramustine, or pharmaceutically acceptable salts thereof.

48. The method according to any one of claims 1 to 26, wherein the additional agent comprises a Bcl-2 inhibitor and / or a Bcl-xL inhibitor.

49. The method according to claim 48, wherein the Bcl-2 inhibitor and / or Bcl-xL inhibitor includes ABT-737, navitoclax (ABT-263), ovatoclax (GX15-070), TW-37, venetoclax (ABT-199), AT101, HA14-1, subtoclax (sabutoclax), S55746, or APG-2575, or pharmaceutically acceptable salts thereof.

50. The method according to any one of claims 1 to 26, wherein the additional agent includes a radiopharmaceutical.

51. A method for treating cancer in a subject requiring treatment, wherein the method applies to the subject, (a) 2,4-dimethoxy-N-(4-methoxy-6-(thiazole-2-yloxy)benzo[d]isoxazole-3-yl)-6-methylpyridine-3-sulfonamide, 【Transformation 3】 or a pharmaceutically acceptable salt thereof, (b) Erasestrant A method comprising the step of administering a substance.

52. The method according to embodiment 51, wherein the cancer is breast cancer.

53. The method according to claim 52, wherein the breast cancer is HR+ / HER2- breast cancer.

54. The method according to claim 53, wherein the HR+ / HER2- breast cancer is ER+ / HER2- breast cancer.

55. The aforementioned ER+ / HER2- breast cancer is classified as ER+ / KAT6a. ｈｉｇｈ The method according to claim 54, wherein the patient has breast cancer.

56. The method according to any one of claims 53 to 55, wherein the breast cancer is resistant to endocrine therapy drugs or chemotherapy drugs.

57. The method according to claim 56, wherein the endocrine therapy agent comprises SERM, SERD, aromatase inhibitor, or CDK inhibitor.

58. The method according to claim 57, wherein the CDK inhibitor includes a CDK4 / 6 selective inhibitor.

59. The method according to claim 57, wherein the CDK inhibitor is PF-07220060, arbocidicib, AT7519, JNJ-7706621, PHA-793887, BMS-265246, milciclib (PHA-848125), R547, ribicilib (P276-00), MC180295, G1T38, ON123300, pluvaranol A, SU9516, ribociclib (LEE011), or BSJ-03-123, palbociclib, abemaciclib, or darpicilib, or a pharmaceutically acceptable salt thereof.

60. The method according to claim 56, wherein the chemotherapeutic agent is epirubicin, doxorubicin, cyclophosphamide, docetaxel, paclitaxel, carboplatin, gemcitabine, lobaplatin, nab-paclitaxel, cisplatin, or capecitabine.

61. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a pharmacopoeia for treating cancer, wherein the pharmacopoeia is formulated to be administered in combination with an additional agent.

62. The use of compounds of formula (I) or pharmaceutically acceptable salts thereof and additional agents in the manufacture of pharmaceuticals for the treatment of cancer.

63. The use of compound 57 or a pharmaceutically acceptable salt thereof in the manufacture of a pharmacopoeia for treating cancer, wherein the pharmacopoeia is formulated to be administered in combination with an additional agent.

64. The use of compound 57 or its pharmaceutically acceptable salts and additional agents in the manufacture of pharmaceuticals for treating cancer.

Images